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This thesis investigated whether inflammation is implicated in breast cancer aetiology and 
survival. For this purpose, circulating markers of inflammation and inflammatory clinical 
disorders were studied in relation to the risk, severity, and survival of breast cancer in a large 
Swedish cohort, the Apolipoprotein MORtality RISk Study (AMORIS), which includes >800,000 
participants in Greater Stockholm area.  
 
Common inflammatory markers: serum C-reactive protein (CRP), albumin, haptoglobin 
and white blood cells (WBC) were examined in relation to breast cancer risk and survival using 
Cox proportional hazard regression models. Proportional odds models were employed to assess 
these markers with regards to breast cancer severity. Systemic inflammation was shown to be 
weakly associated with breast cancer risk and survival. 
 
Allergy, which has been increasingly linked to cancer in part through inflammation, was also 
evaluated using serum allergen-specific IgE against inhalant allergens.  Overall, serum specific 
IgE was inversely associated with the risk of cancer particularly in women. A similar but weaker 
trend was seen for breast cancer.. 
 
Serum lactate dehydrogenase (LDH), a marker of inflammation and metabolic alterations in 
cancer, was studied in relation to cancer survival. Among breast cancer patients, women with 
higher serum LDH were associated with worse overall survival, suggesting its relevance in breast 
cancer growth and progression. 
 
Associations between components of metabolic syndrome, which has often been linked to 
inflammation, and breast cancer survival were evaluated using prediagnostic serum glucose, 
triglycerides, and total cholesterol. In a competing risk analysis using latent class proportional 
hazard models, this association differed by patients characteristics, indicating a complex link 
where competing outcomes are involved.  
 
In summary, findings derived from this thesis contribute to a further understanding of the role 
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Chapter 1: Introduction 
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer-
specific death in females worldwide (1). In 2012, it was estimated that 1.7 million women were 
diagnosed with breast cancer and nearly 522,000 died from the disease. Despite rising incidence 
rates in developing countries during the past two decades (2), about half of all the breast cancer 
cases and 40% of the deaths still occur in more developed countries (1, 3, 4). Consequently, 
these trends also imply that by 2020, most of breast cancer deaths will occur in countries with 
poor resources for healthcare (5). In addition, there is persisting discrepancy in the proportions 
of breast cancer survival across the globe even among similarly developed countries (6). Among 
all cancers in the European Union, breast cancer accounts for the highest health care 
expenditure, with a total of over €6.7 billion or 13% of all cancer-related health care cost in 2009 
(7). Besides inflicting major economic burden, breast cancer diagnosis and recurrence cause a 
deterioration in patients’ quality of life, which in turn affects their overall survival (8, 9). 
Personalised medicine has become a promising strategy to enhance favourable outcomes for 
breast cancer, however, its benefit is limited to cancers expressing known biological targets (10, 
11). Moreover, there is a growing issue of therapy resistance partly due to alternative activation 
of cancer-promoting mechanisms (12). Therefore, comprehensive understanding of biological 
pathways involved in breast cancer development and progression as well as factors affecting 
them is imperative for better utilisation of biological markers for breast cancer intervention.  
 
Inflammation has been acknowledged as one of the mechanisms leading to cancer and its 
progression (13), but its role in breast cancer development is unclear. Adding to this complexity, 
inflammation is characteristically found in an array of clinical disorders such as atopy and 
metabolic disorders, which have also been linked to cancer (14, 15). To gain further insight into 
the intricate relationship between inflammation and breast cancer, clinical markers of 
inflammation, atopy and metabolic disorders were used here to explore the role of inflammation 
and its underlying factors in breast cancer risk, severity and survival using data from the Swedish 
Apolipoprotein Mortality Risk (AMORIS) cohort.  
 
In order to fully understand the scope of breast cancer risk prediction, severity and survival, and 
how inflammation may be implicated in these processes, it is important to briefly review current 
evidence on breast cancer and inflammation, and potential mechanisms underlying their 
association as discussed in the following section. 
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1.1. Breast Cancer 
1.1.1. Biology of breast cancer  
1.1.1.1. The normal breast 
The adult breasts lie horizontally atop the pectoral muscle and ribcage. Anatomically, each breast 
extends from below the clavicle to the centre of the axilla and across to the edge of sternum (16).  
The outer layers of the breast are formed by the skin, with areola and nipple at the centre, and 
underlying fat tissue with embedded blood and lymph vessels and nerves (Figure 1). The intrinsic 
structures of the breast reflect its primary function: to produce milk for lactation. Inner breast 
consists of two main components: the mammary glands and supporting stroma. Primordial 
mammary glands are derived from ectoderm in early of embryonic life and differentiate into 
ductal and lobular-alveolar structures which are present at birth (17, 18). Although breasts of 
male and female newborns are alike, female breasts undergo structural and physiological changes 
later in life under the influence of female sex hormones (19). The development of the ductal 
system, stromal tissue and fat deposition are promoted by estrogens, whereas the development 
of the lobules and alveoli are mainly stimulated by progesterone. However, neither both 
hormones promote lactation, which occurs upon stimulation by prolactin (20, 21).  
 
 





Vasculature of the breast, in particular lymph drainage, is important because of its role in cancer 
metastasis. Lymph passes from the nipple, areola, and lobules to the subareolar lymphatic plexus. 
From here, most (>75%) lymph drains to the axillary lymph node, and continues to the 
clavicular (infraclavicular and supraclavicular) lymph nodes (Figure 2). Lymph may also drain 
directly to the clavicular lymph nodes, or to the parasternal lymph nodes, the abdominal lymph 
nodes, and the opposite breast (16).  
 
 
Figure 2. Lymph vasculature related to the breast (24) 
 
1.1.1.2. Histopathology of breast cancer 
Breast cancer is the malignant tumour that originates in the cells of the breast (25). It is more 
common in the left breast and about half occur in the upper outer quadrant. Pathological 
classification of breast cancer depends on a number of characteristics of the tumour, but largely 
it is based on the cells where it originates from and invasiveness of the tumour. More than 90% 
of breast cancers arise from the ducts and are known as ductal carcinomas, and most of the 
remaining are lobular carcinomas which originate in the lobules (26). When the tumour is 
confined within the ductal or the lobular basement membrane, it is classified as non-invasive 
cancer, or more widely known as ‘carcinoma in situ’. Ductal carcinoma in situ (DCIS) comprises 
the majority of non-invasive breast cancer, followed by lobular carcinoma in situ (LCIS). Both 
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DCIS and LCIS may progress into invasive breast cancer, where malignant cells invade 
surrounding stromal tissue, lymphatic and vascular spaces. Among all breast cancers, invasive 
ductal carcinoma makes up around 75% of all cases, whereas invasive lobular carcinoma 
accounts for 5-10%. Although most invasive ductal carcinomas are of ‘no special type’, a small 
proportion has specific histopathological features and thus falls into the category of ‘special 
type’, which includes medullary carcinoma, tubular carcinoma, mucinous carcinoma, and Paget’s 
disease of the breast (26, 27).  
 
Although histological features of invasive breast cancer cells may resemble those of carcinoma in 
situ, a large discrepancy exists between the two types with regards to clinical management and 
outcomes. This thesis focuses on invasive breast cancer, which is discussed in more detail below.  
 
1.1.1.3. Invasive breast cancer 
According to the World Health Organization’s (WHO) classification of breast tumours, invasive 
breast cancers are characterised by an invasion to adjacent tissue and a tendency to metastasise to 
distant sites (28). As mentioned above, most invasive breast cancers are of ductal origin, among 
which the majority is of no special type (NOS). Besides cell types, other tumour characteristics 
or markers have been utilised in the attempt to better envisage clinical outcomes of invasive 
breast cancer. The terms ‘prognostic’ and ‘predictive’ have often been used in describing these 
markers, and it is important to understand the difference between the two, although a marker 
may fall into both categories. A prognostic factor is described as ‘a measurement that is 
associated with clinical outcome in the absence of therapy or with the application of a standard 
therapy that patients are likely to receive’, which is often seen as the natural history of the 
disease. On the other hand, a predictive factor is ‘a measurement associated with a response or 
lack of response to a particular therapy’, and is considered essential in depicting the interaction 
between such a marker and benefit from a specific treatment (29).  
 
Tumour grade is based on the degree of differentiation of the tumour tissue as assessed in 
histological examination. Currently, the widely recommended method internationally to 
determine breast cancer grade is the Nottingham (Elston-Ellis) modification of the Scarff-
Bloom-Richardson grading system, also known as the Nottingham Grading System (NGS), 
which takes into account the following characteristics of breast tissue: tubule formation as a 
form of gland differentiation, nuclear pleomorphism and mitotic counts (28, 30). An overall 
grade of 1 to 3 is assigned, with 1 reflecting well-differentiated tumour, 2 for moderately-
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differentiated tumour and 3 for poorly differentiated tumour. Higher grade or less differentiated 
tumours have been linked to more aggressive breast cancer and poorer prognosis (31, 32), and 
therefore histological grade is regarded as an important prognostic factor in breast cancer (30).  
 
Assays of hormonal receptors expressed by breast cancer tissue, i.e. estrogen (ER) and 
progesterone receptors (PR), have also been useful in identifying breast cancer patients with 
different clinical profiles, and more importantly, in predicting clinical benefit from endocrine 
therapy (33). Patients with ER-positive breast tumours, which constitute the majority of invasive 
breast cancers (~70%), have shown better response to endocrine therapy compared to those 
with ER-negative status (34, 35). On the other hand, the prognostic relevance of ER and PR is 
still being debated due to a possible confounding by administration of endocrine therapy in early 
breast cancer (36). However, there is evidence that more favourable survival is seen with ER-
positive compared to ER-negative breast cancers in patients who did not undergo endocrine 
treatment (36, 37). Although PR alone is only weakly associated with prognosis, better survivals 
have been reported in systemically untreated patients with both ER-positive and PR-positive 
cancers compared to those with negative expressions of both receptors (38). 
 
Another important tumour marker in breast cancer is the human epidermal growth factor 
receptor 2 (HER2 or cERBB2), a member of the epidermal growth factor receptor family which 
regulates cell proliferation, growth, and apoptosis (39). HER2 gene amplification or 
overexpression of its transmembrane protein are found in 15-20% human breast cancers (40, 
41), and have been linked to worse clinical outcome and recurrence (42–44). HER2 positivity is 
also a predictor of response to treatment with monoclonal antibody targeting the receptor such 
as trastuzumab (45). In addition, together with ER and PR, HER2 is used to identify patients 
with ‘triple-negative’ breast cancers, which are lacking expressions of ER, PR and HER2 and 
comprises approximately 15% of all breast cancer patients (46). Triple-negative breast cancers 
have been consistently linked to poor survival (47, 48), mostly attributed to the lack of receptors, 
i.e. ER and HER2 as therapeutic targets. At the moment, most triple-negative breast cancer 
patients in need of systemic therapy are treated with conventional chemotherapy where clinical 
outcomes are unsatisfactory (49), which prompts the need to establish new molecular target to 
improve survival in these patients. 
 
The availability of high-throughput genomic and transcriptomic data has enhanced the 
identification of novel molecular markers of breast cancer during the last decade. One of the 
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highlights of this new phase in breast cancer research has been the classification of invasive 
breast cancers into at least four major molecular subtypes: luminal A, luminal B, HER2-enriched, 
and basal-like breast cancer (50–53) with more recent work suggesting as many as ten major 
subtypes (54). This finding complements the traditional clinical and pathological classifications of 
breast cancer and has reinforced the notion of breast cancer as a highly heterogenous disease 
(51) with further subtype-specific characterisation needed to allow more personalised treatment 
and improved clinical outcomes. In comparing molecular subtypes with traditional 
histopathological classes, a relatively large degree of overlap exists between luminal and ER-
positive tumours, between basal-like and triple-negative cancers, and between HER2-enriched 
and HER2-positive tumours (53). Additionally, by using proliferation markers such as Ki-67, 
luminal-like breast cancers may be further divided into luminal A-like, which is usually HER2-
negative with low PR and Ki-67 expression, and luminal B-like, which has high Ki-67 and may 
be HER2-negative or -positive (55). Differences in prognosis based on the original four 
molecular subtypes have been reported (50, 56), and assays utilising gene expression signatures to 
estimate prognosis and treatment outcomes such as PAM50, OncotypeDx and MammaPrint are 
now commercially available (52, 57–59). Despite these research advances, the widespread clinical 
deployment of genomic and transcriptomic tools to subtype breast cancer is hampered by the 
relatively high costs and resources needed. For this reason, the traditional immunohistochemical 
subtypes with their relatively well-defined clinical outcomes are still considered adequate in many 






1.1.2. Epidemiology of breast cancer 
1.1.2.1. Incidence, mortality, and survival  
Due to influences of genetic and environmental exposures, the rates of breast cancer occurrence, 
deaths and survivorship vary in different races and geographical regions (61). This thesis utilises 
data from population-based cohorts in Sweden, so that the sections below discuss the 
epidemiology of breast cancer in both the UK and Sweden. 
 
Breast cancer incidence, mortality, and survival in the UK 
Female breast cancer is by far the most common cancer in the UK (62), accounting for about 
30% of all cancer incidence and 50,285 new cases in females in 2011. More cases of female 
breast cancer have been diagnosed yearly over the past decades in the Great Britain, as shown by 
a 72% increase in European age-standardised incidence rates between 1975-1977 and 2009-2011 
(Figure 3). Incidence rates only steadily increased (1-2% annually) between the mid-1970s and 
late 1980s. Higher increments observed during the 1980-1990 transition period was suggested to 
be caused by the introduction of national screening programmes (63), and the rates have 
relatively stabilised ever since. Similar trends from 1993 onwards (when data became available) 
are observed in the UK (64). Incidence rates are highest in older women, supporting a link with 
hormonal status. It was estimated that by the age of 50, around 10,000 women are diagnosed 
with breast cancer in the UK, whereas 80% of all breast cancer diagnoses are in women over 50s, 
and 24% in those aged 75 and over (64).  
 
 
Figure 3. European age-standardised incidence rates of female breast cancer per 100,000 population, 




Despite the advancement of its detection and treatments, breast cancer remains a leading cause 
of death in the UK, with 11,643 deaths in females in 2012 (64). A reduction in mortality rates by 
36% have been observed between 1971-1973 and 2010-2012 (Figure 4), although an increase 
from the early 1970s until the mid-1980s was seen before the rates continued to decline. The 
highest mortality rates are observed in older populations, with an average of 46% breast cancer 
deaths in women aged 75 and older during the period 2010 to 2012 (64).  
 
 
Figure 4. European age-standardised mortality rates of female breast cancer per 100,000 population, UK, 
1971-2012 (64). 
 
The UK has seen improvements in survival of breast cancer during the past decades. A 40% 5-
year survival was observed during 1971-1972 in England and Wales, and this figure was 
predicted to reach 78% during 2010-2011 (64). As shown in Figure 5, the greatest gains in 
survival were seen in the 1990s, followed by continued but smaller annual increments 
throughout the 2000s. Some factors thought to contribute to the improved survival prior to the 
2000s are mammography screening, which resulted in less advanced disease at diagnosis, 
innovations in breast cancer therapy such as adjuvant chemotherapy and tamoxifen, while 
improvement in later years is considered to result from health reforms directed towards better-





Figure 5. Age-standardised 5-year net survival of women with breast cancer aged 15-99, England and 
Wales, 1971-2011 (64) 
 
Breast cancer incidence, mortality and survival in Sweden 
Breast cancer is the most frequently diagnosed cancer in women in Sweden, with 8,382 new 
cancer cases or 30.3% among all cancers in females in 2011 (66). Increasing annual incidence 
rates of female breast cancer incidence are presented in Figure 6. Relatively weaker increments 
during the recent twenty years are seen compared to early 1990s, which may also be attributed to 
screening programmes. More than 80% breast cancer cases were diagnosed in women aged 50 




Figure 6. Age-standardised incidence rates of female and male breast cancer, Sweden, 1960-2010 (66). 
 
As one of the most common causes of death in women, breast cancer contributed to 
approximately 42.8 deaths per 100 000 women aged 40 and over in Sweden in 2009 (67). From 
1972 to 2009 (Figure 7), a yearly decrease of 0.98% in breast cancer mortality rates is observed in 
women aged 40 years and older. This trend was only modestly affected by the start of screening 
program both nationwide and in county-specific observations (68), which results in a relatively 
consistent decline over the years. 
 
 
Figure 7. Age-standardised mortality rates breast cancer in females aged 40-79 in Sweden, 1974-2004. 
Adapted from Haukka and colleagues (69). 
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The relative 5-year survival of breast cancer patients in Sweden has increased from 64% in the 
1960s to an estimated 88% during 2009-2013 (70, 71). As depicted in Figure 8, the greatest 
improvement in breast cancer survival occurred in the late 1970s. Advancement in treatment or 
national policies in breast cancer management are unlikely explanations to these early trends (72). 
Possible underlying factors include increased awareness of the advantage of breast cancer 
screening prior to the commencement of the screening programmes and the changing natural 
history of breast cancer and its determinants including lifestyle (70). 
 
 




Overall, breast cancer cases are still increasingly being diagnosed in both the UK and Sweden, 
whereas deaths from the disease decline over the years, and this trend is consistent with other 
European countries (2, 68). Screening programmes played an important part in the incidence and 
mortality trends. Following the start of national screening programmes in the late 1980s, a peak 
in diagnosis rates are seen in the UK and Sweden. However, a steep decrease in mortality rates 
following this time point was only seen in the UK. Mortality trends in Sweden are similar before 





Figure 9. Annual mortality (a) and incidence rates (b) per 100,000 population and 5‐year net survival (%) 
(c): breast cancer, women diagnosed aged 50–69 years in England and Sweden during 1981–2009 (73). 
 
With regards to breast cancer survival estimates, there is apparent discrepancy between the two 
countries. Although marked improvement have been seen in England since the mid-1990s, 
survival remains lower compared to comparable developed countries including Sweden (6). 
Rather than data quality and changes in classification, these patterns are relevant to later 
diagnosis or differences in treatment, indicating quality in breast cancer management as the main 
determinant (74). Improvement in survival in Sweden tends to be less prominent in comparison 
to England especially after the 1990s (73), which is consistent to the comparable incidence rates 
and discrepancy in mortality rates between the two countries (Figure 9). The plateau-like trends 
observed for mortality and survival estimates in Sweden may be caused by a ceiling effect due to 
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high quality of breast cancer care in the country since the beginning of observation periods (65). 
Despite the steady narrowing of breast cancer survival disparity between the two countries and 
internationally, continuous surveillance is needed to ensure ongoing progress. 
 
1.1.2.2. Breast cancer risk factors 
Although it is estimated that 1 among 8 women will develop breast cancer in their lifetime, about 
70% of them have no identifiable risk factors (75). Besides older age, a number of factors have 
been associated with higher risks of getting diagnosed with invasive breast cancer. Among the 
strongest risk factors are family history, inherited genetic mutations, previous breast cancer, 
mammographically dense breast, LCIS and atypical hyperplasia, and radiation to the chest (76–
78). A family history of breast cancer in one first-degree relative has been estimated to increase 
the risk of getting diagnosed with breast cancer by 1.8 times compared to a lack of family history 
(79), and this risk multiplies with more numbers of first-degree relative with breast cancer, 
particularly at younger age. Among inherited genetic mutations, which accounts for 5-10% of all 
breast cancers, the most important by far are mutations of tumour suppressor genes BRCA1 and 
BRCA2 (77). The two genes were identified as breast susceptibility genes through linkage 
analysis in the mid-1990, and are associated with breast cancer risk of around 57% for BRCA1 
and 49% for BRCA2 mutation carriers at age 70 (80). However, mutations of BRCA1 or BRCA2 
only account for 15-20% of familial breast cancers (81, 82), leading scientists to believe that 
intermediate- and low-penetrance genes may jointly explain the remaining proportion of genetic 
susceptibility of breast cancer (83–86). Investigation into such polygenic susceptibility has 
advanced dramatically owing to genome-wide association studies (GWAS) (87), which has 
increasingly recognised common low-penetrance alleles associated with breast cancer risk such as 
variants of telomerase reverse transcriptase (TERT) and ataxia telangiectasia mutated (ATM) 
genes (88). In a recent meta-analysis including 11 GWAS on over 120,000 women, 15 novel low-
penetrance genes were further identified, which altogether explained a further ~2% of breast 
cancer risk (89). It was estimated that assuming all the susceptibility genes could be identified, 
the half of the population at highest risk based on genetic scores would account for 88% of all 
breast cancer cases (90). Additionally, interaction between genes and environmental risk factors 
in breast cancer has been shown to affect the risk of breast cancer (91, 92), pointing toward the 
role of epigenetic alterations (93).  
 
Reproductive factors have also been consistently associated with breast cancer risk (75, 94), 
which underlines the role of hormones. Higher risk of breast cancer has been reported with an 
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earlier age of menarche, later age of menopause, nulliparity, and late age at first childbirth, all of 
which are relevant to the cumulative number of ovarian cycles (95–97). Correspondingly, altered 
levels of endogenous sex steroid hormones have been linked to breast cancer incidence. Higher 
circulating estrogen and its metabolites corresponded to increased breast cancer risk among 
postmenopausal women (94, 98), and this association differed by estrogen metabolic profile (99). 
Among premenopausal women, the role of androgens has been implied, with positive 
associations observed between breast cancer risk and levels of testosterone, androstenedione, 
and dehydroepiandrosterone sulphate (DHEAS) but not sex hormone binding globulin (SHBG) 
(100). On the contrary, a reduced risk of breast cancer was associated to higher progesterone 
levels in the same study, For circulating prolactin, a positive association with breast cancer has 
been found among postmenopausal women using hormone replacement therapy (101). The 
impact of exogenous estrogen is further shown by an increased risk of breast cancer associated 
with oral contraceptives and hormone replacement therapy per se (102–105). On the other hand, 
a reduced risk of breast cancer has been observed following breastfeeding, and this association is 
independent of estrogen-driven risk factors including age at menarche, menopausal status, parity, 
and age at first childbirth (106). 
 
Breast cancer susceptibility has been increasingly linked to lifestyle-related factors (107). Alcohol 
consumption has been repeatedly shown to correspond to a moderate increase in breast cancer 
risk, with an estimated 7-10 % risk increase for each additional 10g per day intake of alcohol 
(107, 108). Smoking, on the contrary, is not associated with breast cancer susceptibility apart 
from its correlation to alcohol consumption (108). Obesity has also been linked to an increased 
risk factor of postmenopausal breast cancer, with a 5 kg/m2 increase in body mass index (BMI) 
corresponds to around 10% higher risk of breast cancer (109). There is also evidence that the 
risk of breast cancer increases with dietary fat intake and a lack of physical exercise (110, 111), 
further indicating a potential role of lifestyle modification in breast cancer prevention strategies. 
 
Demographic factors apart from age also contribute to breast cancer susceptibility. Compared to 
other ethnicities, breast cancer risk is higher in Ashkenazi Jewish populations, which is attributed 
to the high frequency of BRCA1 and BRCA mutations (112). Higher breast cancer incidence 
rates have been observed in women with higher socioeconomic status (113). However, multiple 
indicators of socioeconomic status and their close correlations to other risk factors such as race 
and lifestyle indicate its complex relationship with breast cancer risk (114). Other factors which 
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have been linked to increased breast cancer risk include height, exposure of diethylstilbestrol 
(DES), and history of endometrium, ovary, or colon cancer (77, 115, 116).  
 
1.1.2.3. Breast cancer screening 
Screening for breast cancer is performed with mammography, clinical breast examination, breast 
self-examination, and MRI. Mammographic screening has been suggested to result in a 15-20% 
risk reduction of deaths from breast cancer during 7 to 12 years of follow-up (117, 118). 
However, it is also associated with an estimated 19% of cancers being overdiagnosed, i.e. 
diagnosis of cancers which would not become clinically apparent without screening (11, 119). 
Additionally, a cumulative risk of a false-positive result of 61% has been reported for a 40- or 50-
year old woman undergoing 10 years of annual mammogram. Despite the lack of its impact on 
survival, false-positive may cause harm to the patients through unnecessary invasive procedures, 
additional costs and psychological stress (118).  
 
Since 2009, the U.S. Preventive Services Task Force has recommended that annual screening 
mammography is only performed for women aged 50 to 74 years, because the harm of screening 
in women beyond these age range is considered to outweigh the benefit (120). The same 
recommendation has been made by the Canadian Task Force of Preventive Health Care, whereas 
the U.K. National Health Service Breast Screening Program is using a slightly different cut-offs 
of 47-73 years and 3-year screening intervals. The decision of screening for younger women 
should be made case by case, and take into account individual risk of developing breast cancer. 
Baseline risk assessment is therefore an integral part of screening, and a number of risk 
prediction models have been proposed to provide the information. The most widely used tool to 
date is the Gail model, which takes into account age at menarche, age at first birth, number of 
first-degree relatives with breast cancer, number of previous breast biopsies, and presence of 
atypical hyperplasia to recognise those at increased risk of developing breast cancer (121). 
Despite some limitations when being applied to a multiethnic population, this model has been 
integrated in several screening guidelines including those of the U.S. National Comprehensive 
Cancer Network (122). Nevertheless, it is of note that for women with known or suggestive 
genetic predisposition for breast cancer, a different screening approach is recommended which 





Breast cancer risk reduction through pharmacologic intervention include blockade of ER using 
selective ER modulators such as tamoxifen, and aromatase inhibitors such as exemestane. The 
American Society of Clinical Oncology recommends that the use of these agents should be 
discussed as an option to reduce the risk of invasive breast cancer, specifically ER-positive breast 
cancer in women at increased risk of breast cancer aged 35 years and older (124). Identification 
of those at increased risk is based on genetic predisposition, 5-year breast cancer risk of 1.7% or 
higher as assessed by the Gail model, and prior radiotherapy to the chest at young age and 
history of LCIS (122). A risk reduction in ER-positive breast cancer of 31-67% has been 
reported following chemoprevention with tamoxifen compared to placebo, however, no impact 
on breast cancer mortality is observed in previous studies (124).  
 
1.1.3. Management of breast cancer 
The management of breast cancer has evolved dramatically during the past few decades. Whilst 
treatment modalities are beyond the scope of this thesis, the following section briefly reviews 
current principles of primary breast cancer management to allow understanding into various 




Diagnostic work-up for breast cancer is performed for all symptomatic patients, and for those 
suspected to have breast tumour through breast screening. A triple assessment approach is 
recommended by most European professional bodies (125), which includes clinical assessment, 
mammography and/or ultrasound imaging, and core biopsy and/or fine needle aspiration 
cytology. It is advised that these assessments are carried out at the same visit (126). Clinical 
examination includes bimanual palpation of the breast and locoregional lymph nodes and an 
assessment for distant metastasis. MRI is not routinely recommended except in particular cases 
such as inconclusive results from conventional imaging. Detailed personal medical history, 
laboratory examination including full blood count, liver and renal function test, and menopausal 
status assessment should also be performed. Pathological diagnosis is based on a core needle 
biopsy, preferably by ultrasound or stereotactic guidance, or if not possible, at least a fine needle 
aspiration indicating carcinoma. Assessment of distant metastasis as well as comprehensive 
laboratory examination are not routinely performed in early breast cancer due to their lack of 




WHO classification and the tumour-node-metastases (TNM) staging system should be used in 
making final pathological diagnosis of breast cancer, and includes information on tumour size, 
regional lymph node status, and distant metastasis. In addition to tumour stage, other clinical 
parameters including age, ER expression and histological grade are used in baseline risks 
assessment using several scoring systems estimating breast cancer prognosis, such as Nottingham 
Prognostic Index (NPI), Adjuvant! Online, or PREDICT score (127–129). When applicable, risk 




Surgery remains the backbone of treatment for operable breast cancer. During the past 30 years, 
breast-conservation surgery (BCS) such as wide local excision has become the treatment of 
choice particularly in more developed countries. In the current guidelines, the target of local 
recurrence rates after wide excision and radiotherapy is <0.5% per year, and should not exceed 
10% overall. In some patients, mastectomy is still performed due to reasons such as locally 
advanced breast cancer, positive surgical margins after multiple resections, or patient choice 
(125). Locally advanced breast cancer, defined as inoperable breast cancer which has not spread 
to distant sites, usually includes large operable primary breast tumours (stage IIB, IIIA) and/or 
those involving the skin or chest wall and/or those with extensive lymphadenopathies (stage 
IIIB, IIIC) (130). Following mastectomy, immediate or delayed breast reconstruction is 
recommended to achieve acceptable cosmetics. In selected patients, primary systemic therapy 
may precede surgery in order to downsize the tumour. In the case of downsizing, the choice of 
treatment is based on the assessment of clinical stage after primary therapy (60). 
 
Axillary lymph node staging 
Regional lymph node status is an important prognostic indicator in primary breast cancer. In 
previous years, axillary clearance had been the treatment of choice, but it is associated with 
lymphoedema in the upper limb especially when combined with radiotherapy. Currently, sentinel 
lymph node biopsy (SLNB) rather than full nodal clearance is the standard of care for axillary 
staging (131). Conventional axillary clearance is only recommended following detection of 
macrometastatic spread in the sentinel node if no radiotherapy is planned (60). This is because 
data from recent clinical trials comparing axillary dissection and axillary radiotherapy following 1-
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2 positive sentinel lymph nodes in T1-T2 primary breast cancer showed equally low axillary 
recurrence rates, although lower adverse effects are observed with radiotherapy (132). However, 
other clinical trials showed no survival benefit of axillary dissection compared to SLNB alone in 
similar groups of breast cancer patients with micro- or macrometastasis (133, 134), which 
indicates that further considerations are needed in treating axillary spread of the disease. 
 
Radiotherapy 
Postoperative radiotherapy is strongly recommended after BCS (125) and after mastectomy with 
tumour size 5 cm or greater, a positive macrometastatic sentinel lymph node but no axillary 
dissection, or 1-3 involved nodes and adverse pathology (60). A locoregional recurrence risk 
reduction of roughly two thirds to three quarters has been reported following mastectomy (135). 
Whole breast radiation therapy with or without boost is the current standard of practice, 
although consideration of partial breast irradiation may be made for selected patients based on 
age and tumour characteristics (122). It is common for radiotherapy to follow chemotherapy 
when the latter is indicated. 
 
Systemic therapy 
Primary systemic therapy may take place prior to surgery and is known as ‘neoadjuvant’ 
treatment, and may also follow surgery as ‘adjuvant’ treatment. Systemic adjuvant treatment 
should be considered based on predicted sensitivity to particular treatment methods and benefit 
from their use and individual risk of relapse (125).  
 
Chemotherapy 
Also known as cytotoxic therapy, chemotherapy utilises chemical agents targeting vital cellular 
processes with no specificity towards cancer cells. Consequently, this treatment is associated with 
toxicity of the drugs to otherwise healthy tissues (26). The 2015 St. Gallen consortium 
recommended that the decision to administer adjuvant chemotherapy should be based on the 
intrinsic type of breast cancer, with the selective help from genomic examinations when available 
(60). For instance, in luminal B-like cancers, while there is pronounced benefit from 
chemotherapy, it could be omitted in cases with low-scores on first-generation genomic tests 
such as Oncotype Dx. For triple-negative breast cancers, however, chemotherapy remains the 
main component of systemic therapy, with anthracycline and taxane-containing regimens as the 
recommended treatment (60). Recently, the Early Breast Cancer Trialists’ Collaborative Group 
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(EBCTCG) reported that clinical outcomes in breast cancer patients treated by taxane- or 
anthracycline-based adjuvant chemotherapy only slightly vary by known prognostic factors 
including age, nodal status, rumour diameter or differentiation, ER status, or use of tamoxifen 
(136). Nevertheless, individual absolute benefit while considering side effects of chemotherapy 




Adjuvant endocrine therapy has been routinely administered to all patients with ER-positive 
tumours, irrespective of chemotherapy and/or targeted therapy. Tamoxifen is the treatment of 
choice in premenopausal patients, although a switch to letrozole, an aromatase inhibitor, may be 
beneficial after the patient becomes postmenopausal (125). An aromatase inhibitor is also the 
choice for postmenopausal breast cancer patients (126). In addition, endocrine therapy as a 
neoadjuvant treatment has been increasingly recommended in treating postmenopausal patients 
with endocrine-responsive diseases, especially luminal-like breast cancers (60). 
 
Biological therapy 
Therapy targeting biological constituents of cancer cells has been regarded important in 
addressing the heterogeneity of breast cancer as well as other types of cancer. The use of 
trastuzumab, a monoclonal antibody binding the HER2, was first approved in the early 2000s 
(44), and despite the rapid growth of targeted cancer therapies, it has remained the most widely 
used biological therapy in breast cancer to date. Targeting HER2 using trastuzumab is strongly 
recommended in patients with HER-positive breast cancers, and has been associated with 
improved disease-free and overall survival (45, 125). Besides its use in adjuvant settings, HER2-
targeted therapy is also recommended as a first-line treatment in HER2-positive diseases, except 











1.2.1. Biological basis of inflammation  
Inflammation is an immunological process elicited by immune effectors, usually in response to 
tissue injury or infection. As defined by Cornelius Celsus in the 1st century AD, there are four 
cardinal signs of inflammation: color, dolor, rubor and tumor, which in Latin mean heat, pain, 
redness and swelling. The fifth sign, functio laesa or decrease in function, was later added by 
Rudolph Virchow in 1858 (138). A set of cellular processes are known to underlie inflammation 
and these clinical signs. Following an invasion by a pathogen, antigen-presenting cells (APC) 
such as macrophages and dendritic cells (DCs) may recognise antigens expressed by the 
pathogen through pattern-recognition receptors (PRRs) and engulf the pathogen, a process 
known as phagocytosis (139). After APCs have degraded the pathogen, they secreted 
inflammatory mediators such as cytokines and chemokines, substances with abilities to affect the 
behaviour of and attract other cells with relevant receptors, respectively. Cytokines and 
chemokines released by activated APCs initiate the inflammation cascade which produces the 
aforementioned clinical signs. The primary role of inflammation is survival upon injury or 
infection, and therefore, components of innate immunity such as neutrophils and other 
inflammatory cells and proteins are recruited from the blood into the site of infection in order to 
eliminate the pathogen. In addition, APCs are transported by lymph to nearby lymphoid tissue, 
where they activate adaptive immune response. This triggered recruitment of adaptive immunity 
components including antibody and effector T cells to the site of inflammation. Vasodilation and 
increased vascular permeability which occur during inflammation result in the redness, heat and 
swelling, whist pain is caused by inflammatory mediators such as prostaglandins. Inflammation 
and phagocytosis may also be triggered by the activation of a group of plasma proteins known as 
complement. Activation of the complement leads to coating or opsonisation of the pathogen’s 
surface by complement fragments, and this complex is recognised by macrophages, after which 
phagocytosis takes place (139). 
 
As mentioned above, two major types of immune mechanisms are known: innate or cellular and 
adaptive or humoral. Innate immune mechanisms are the first line of defence against invading 
pathogens characterised by immediate but short-term and non-specific immune responses 
carried out by macrophages, neutrophils, eosinophils, basophils, inflammatory mediators, natural 
killer (NK) cells and the complement (140). Adaptive immune mechanisms principally comprise 
lymphocytes with specific reactivity towards antigens and require a lag time to activate, usually a 
few days. However, the immune responses generated are long-lasting, specific, and unlike innate 
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immunity, they retain ‘memory’, i.e. repeated infection by the same pathogen will generate more 
amplified responses. The two classes of lymphocytes, i.e. B cells and T cells, give rise to antibody 
responses upon stimulation to B-cell receptor (BCR) and cell-mediated immune responses 
following T-cell receptor (TCR) stimulation, respectively. Activated B cells secrete antibodies, 
which are prns called immunoglobulins (Ig). At least five classes of immunoglobulins have been 
identified: IgA, IgD, IgE, IgG, and IgM (140). Protection against invading pathogens is mostly 
carried out by IgG and IgM, whereas IgA is important in mucosal immunity, IgE in allergy and 
parasite infection, and IgD functions mainly as an antigen receptor. Activation of B-cells upon 
antigen recognition is assisted by a class of T-cells known as T helper (TH), mostly of the TH2 
subclass. Another class of T cells, cytotoxic T-cells (CTL), eliminate pathogens through inducing 
apoptosis or cell death upon stimulation by another T helper, TH1. TH1 also stimulates 
phagocytosis by macrophages, and therefore the balance between TH1 and TH2 determines the 
dominant type of adaptive immune responses against the pathogen. 
 
As seen in Figure 10, both innate and adaptive immunity are interrelated and may underlie 
inflammation. For instance, antigen presentation by macrophages stimulates naive T cells to 
become armed T cells which are specific for that antigen. When the same antigen is in contact 
with surface immunoglobulin in B cells, armed T helper cells will recognise the antigen and 
secrete molecules to activate the B cells, the latter of which subsequently proliferate and 
differentiate into specific antibodies (139). Complement proteins also mediate antibody-mediated 
responses; hence it is a part of both innate and adaptive immunity. Furthermore, mast cells, the 
main effector of antibody-mediated allergic responses, may also stimulate phagocytosis in 
bacterial infection, indicating a role in innate immunity (141). All these immune responses are 
largely regulated by cytokines such as interferons (IFN), tumour necrosis factor (TNF) and 
interleukin-1 (IL-1) (140). 
  
Systemic inflammation may follow local inflammation, resulting in general clinical signs which 
are induced by circulating cytokines including fever and an acute-phase response, i.e. 
modification of proteins synthesised and secreted by the liver cells into the circulation. These 
proteins induced by cytokines are called the acute-phase proteins, some of which have been 
shown to be involved in immune responses against invading pathogens (139). When the 
infectious agents are eliminated, a resolution of inflammation takes place, with the purpose of 
restoring tissue function (138). This is indicated by a flow of monocytes which differentiate into 
macrophages, the latter will engulf the dead bacteria or apoptotic cellular debris. When the cause 
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of inflammation is not resolved, a chronic inflammation may develop, mostly localised to the site 
of infection. This may result in specific local inflammatory responses such as formation of 




Figure 10. The interplay between innate and adaptive immune responses (142). 
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1.2.1.1. Inflammation, homeostasis and chronic diseases 
During the past few decades, chronic inflammation has increasingly been described in conditions 
or diseases where the initiating trigger is unlikely to be an infection or wound, for instance 
obesity, diabetes, atherosclerosis, and allergy (138), the latter of which will be further discussed. 
An interesting observation is that a vicious cycle seems to take place, for instance inflammation 
may occur secondary to obesity, but chronic inflammation may also promote obesity-associated 
diabetes (143). A recent perspective of inflammation as a mechanism to preserve homeostasis 
has been proposed. Homeostasis reflects a complex machinery which maintains key regulated 
variables within an acceptable range, which may operate at the level of the entire organism, 
within tissue compartments, and within individual cells (144). For some variables such as body 
temperature, the aforementioned ranges or ‘set points’ are fixed at certain values, and any 
changes secondary to diseases will be immediately restored. However, in metabolic conditions 
such as obesity, continuous adjustments of set points occur to adapt with the cumulative changes 
inflicted by the environment, which in this case would be the increasing body weight and 
adiposity. Loss of homeostasis hence follows, inducing various tissue stressors such as 
endoplasmic reticulum stress, hypoxia and oxidative stress which are thought to evoke immune 
responses leading to inflammation (145). As a protective response, the resulting inflammation is 
engaged to defend and restore physiological functions by overriding perturbed homeostatic 
controls. Nevertheless, changes enforced by the inflammatory responses may be excessive or 
inappropriate, further worsening the conditions and leading to chronic pathological states. 
 
1.2.1.2. Allergic inflammation 
Deleterious effects of inflammatory responses are also observed in allergic disorders. The terms 
allergy and atopy have been used interchangeably in the literature to describe an abnormal 
adaptive immune response directed against non-infectious environmental substances or allergens 
such as pollen and food (146).  However, atopy specifically refers to the predisposition to 
develop IgE-mediated immunological reactions to environmental allergens  (147). In most cases, 
these reactions occur after the individual has become sensitised to the particular allergen, by 
producing specific IgE against it. On the other hand, allergic reactions, or traditionally known as 
‘hypersensitivity reactions’, do not necessarily involve IgE, although a prior sensitisation against 
allergens may take place. Allergic inflammation, which occurs following an allergen exposure to 
sensitised subjects, may be classified into three temporal phases: early-phase, late-phase, and 
chronic (146). Early-phase reactions, also known as the type I hypersensitivity reactions (139), 
occur within minutes of allergen exposure and result from an immediate release of inflammatory 
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mediators by mast cells. In sensitised individuals, mast cells residing in tissues already have 
allergen-specific IgE bound to their surface high-affinity IgE receptors (FcεRI). Activation of 
mast cells occurs upon interaction with a multivalent allergen, leading to cross-linkage of IgE on 
their surface and degranulation or secretion of inflammatory mediators including histamine and 
cytokines such as TNF-α and IL-16 (141). Mast cells degranulation accounts for the local early-
phase reaction, or a systemic one which is known as anaphylaxis. Some inflammatory mediators 
take longer time to be released and exerting their actions, and are responsible for late-phase 
reactions, which are usually observed 2-6 hours after allergen exposure, and often peak after 6-9 
hours. In addition to delayed release of mast cells mediators, this late-phase reactions are also 
indicated to be attributed partly to allergen-stimulated T cells, eosinophils and monocytes (146). 
When a continuous or repeated allergen exposure occurs, inflammation may persist, invoking 
both innate and adaptive immune responses. As in asthma and chronic allergic rhinitis, this 
chronic allergic inflammation is associated with morphological and functional changes in 
affected organs such as epithelial tissue remodelling. It is, however, unclear how early- and late-
phase reactions develop into chronic inflammation, and why some allergic individuals only 
develop early-phase reactions without experiencing the later phases (139). 
 
1.2.1.3. Serum markers of inflammation 
Systemic inflammation may follow local inflammation, and thus inflammatory-related proteins 
and cells may be detected in the circulation. These inflammatory markers have been useful in 
assessing inflammation-related conditions and diseases. Common clinical markers of 
inflammation were studied in this thesis. Serum leukocytes or white blood cells (WBCs) are 
routinely measured in the complete blood count and provide an estimation of their main 
components in the circulation: lymphocytes, neutrophils, eosinophils, basophils and monocytes, 
all of which are involved in innate and adaptive immunity (139). Also widely assessed as an 
indicator of inflammation are acute phase proteins, which are usually detected in the serum in 
abnormal amounts during inflammation. Among this group, C-reactive protein (CRP) is the 
most widely used marker in the context of both clinic and research. In healthy individuals, only 
minimal or no amount of CRP is detectable in the serum. A clinically raised level of CRP (10 
g/L) indicates acute inflammation, whilst detectable but lower levels have been suggested to 
indicate low-grade inflammatory state (148). In addition to its role as a ‘positive’ indicator for 
inflammation, CRP is also known as a soluble PRR, which plays a role in innate immunity by 
opsonising invading pathogens and bind apoptotic debris (142). Haptoglobin, another acute-
phase reactant, is also produced excessively by the liver during inflammation. Haptoglobin binds 
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haemoglobin released from red blood cells (RBC) during haemolysis, and therefore has been 
used as a marker for haemolytic anaemia in the clinic. However, a growing evidence shows that a 
specific haptoglobin phenotype, haptoglobin 2-2, exhibit antibody-like activity against bacteria, 
which suggests a role in immune responses (149). Some proteins are produced in lesser amounts 
by the liver during inflammation and are therefore known as ‘negative’ acute phase reactants. 
Among this category, albumin is the most frequently assessed, and its level has been shown to be 
inversely correlated to positive acute phase proteins such as CRP (150).  
 
In addition to WBC and acute phase proteins, more recently established inflammatory markers 
have also been increasingly studied. Many studies directly measure systemic levels of cytokines 
such as interleukin-6 (IL-6), IL-8 and TNF-α, which have been investigated with respect to 
cancer (151–153). Another approach is to assess other pro-inflammatory markers which are 
regulated by these cytokines such as neopterin (154, 155). Nevertheless, measurements of these 
markers are less widely available compared to the conventional ones and they are not routinely 



















1.3. Inflammation and Breast Cancer 
1.3.1. Linking inflammation and cancer 
In 1863, Rudolf Virchow made the first connection between inflammation and cancer upon 
observing the infiltrates of leukocytes among neoplastic tissues (156). However, it was not until 
the last decade that scientists established the importance of inflammation in cancer. Grivennikov 
and colleagues summarised the link between inflammation and cancer to be multifaceted (157), 
in which inflammation may play a role in every stage of carcinogenesis, and reciprocal causations 
may take place. This is best shown in Figure 11, where a distinction can be drawn between 
inflammation that occurs prior to cancer and inflammation that follows cancer or its therapy. 
Whilst therapy-related inflammation is beyond the scope of this thesis, the two main extents of 
how inflammation is linked with cancer are further described below. 
 
 






1.3.1.1. Inflammation and carcinogenesis 
The historical view of cancer can be summarised by the statement ‘wounds that do not heal’ 
(158), which clearly illustrates the role of inflammation, particularly the chronic type, in 
preceding cancer development. Inflammation is thought to be capable in triggering both tumour 
initiation and promotion. With respect to tumour initiation, inflammatory response may increase 
the formation of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI), which 
may induce mutation and genomic instability leading to malignant transformation (157, 159). 
However, it is uncertain whether ROS and RNI can initiate carcinogenesis independent of 
factors underlying inflammation, and it is thought that pro-inflammatory cytokines may enhance 
their intracellular tumour-initiating effects (157). In the context of tumour promotion, a number 
of signalling pathways linking chronic inflammation and cancer have been identified, including 
signal transducer and activator of transcription 3 (STAT3) and (nuclear factor kappa beta) NF-
κB (160, 161). Pro-inflammatory cytokines may trigger the activation of STAT3 and NF-κB, 
which further activate genes responsible for cell survival, proliferation, and growth, as well as 
angiogenesis, invasiveness, motility, chemokine, and cytokine production, eventually leading to 
further inflammatory response and tumour promotion (162). These common pathways between 
inflammation and cancer may also imply that in some cancers, factors triggering inflammation 
are the real instigator of carcinogenesis, and that chronic inflammation may be a mediator rather 
than an independent promoter of cancer development. Correspondingly, STAT3 and NF-κB are 
also found to be activated by inflammation-related environmental and dietary exposures such as 
tobacco smoking, obesity, alcohol and infectious agents (161, 163), which further suggest the 
importance of underlying factors of inflammation in carcinogenesis. 
 
1.3.1.2. Cancer-related inflammation 
The two faces of immune responses in presence of cancer have been widely accepted: tumour-
promoting and tumour-antagonizing. The first was described by Hanahan and Weinberg (13) as 
an ‘enabling characteristic’, which inadvertently supports cancer cells to thrive and disseminate. 
In healthy individuals, there is likely equilibrium between the primary function of immune 
system, which is to recognise and kill pathogens, with the secondary one: wound healing and 
immunosuppression. Nevertheless, the latter function is thought to predominate in cancer-
related inflammation (164). As an evidence, instead of the conventional anti-pathogen 
neutrophils and M1 macrophages, alternatively-activated or polarised macrophages (M2) and 
neutrophils predominate tumour microenvironment (165). These inflammatory cells are directly 
recruited by tumour cells. Similar immunosuppressive activities in cancer have also been shown 
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with other immune effectors such as T-cells, B-cells, mast cells and DCs (157, 166). This 
evidence implied an involvement of both innate and adaptive immunity in tumour-related 
immunosuppression.  
 
Tumour cells may also recruit myeloid-derived suppressor cells (MDSCs), a population of 
haemopoietic cells comprising immature precursors of DCs, granulocytes and 
monocytes/macrophages (167). MDSCs express specific markers such as CD11b and Gr1, and 
are suggested to being able to incapacitate T-cells. Additionally, MDSCs serve as a pool of cells 
replenishing polarised immune effectors in tumour microenvironment by cross-differentiating 
following stimulation by tumour-derived cytokines (168, 169). Recent evidence also showed that 
MDSCs promote mammary invasion by secreting cytokines that activates fibroblast migration, 
which emphasised their potential role in disease progression (170). 
 
Despite abilities of a tumour to induce immune tolerance, anti-tumoural immune responses 
involving T-cells and NK cells have been reported in human cancers with a relevant significance 
in prognosis (171, 172). Nevertheless, cancer may directly counter anti-tumoural immune 
responses by secretion of inflammatory mediators such as transforming growth factor-β (TGF-
β), which suppresses the activity of CTLs and NK cells (173). Moreover, cancer is a 
heterogeneous population of cells. Therefore, subpopulations of weakly immunogenic cells may 
survive and form solid tumours in spite of effective elimination of highly immunogenic cancer 
cells by the immune system. This process is known as immunoediting (174). Targeting the 
balance between the tumour-promoting and -antagonising effects of cancer-related inflammation 
may be a promising strategy to direct immune system toward eliminating cancer.  
 
1.3.2. Inflammation and breast cancer 
As in other solid tumours, inflammation may be involved in breast cancer promotion through 
the STAT3 and NF-κB pathways (175, 176). Similarly, leukocyte infiltrates have been suggested 
to play a role in breast cancer development and progression (177). The presence of B-cells has 
been reported in nearby lymph nodes and stroma of early breast cancer, as well as serum specific 
antibodies against tumour-associated antigens, which have been associated with worse prognosis 
(178). On the other hand, T-cells are more common in invasive breast cancer and have been 
linked to more favourable survivals (179, 180), implying a role of immune surveillance. 
Nevertheless, increased helper T cells and its increased ratio to CTLs are correlated to a poor 
prognosis in breast cancer (181), indicating tumour-associated immunosuppression. Similar 
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prognostic significance has been observed with other immune infiltrates such as macrophages 
and MDSC (181). 
 
The role of systemic inflammation is subject of ongoing investigations in breast cancer. With 
regards to breast cancer prognosis, CRP levels at diagnosis or before treatment have been 
unequivocally shown to be associated with prognosis in a meta-analysis including ten studies, 
with a hazard ratio (HR) of 2.08 (95% confidence intervals [CI] 1.48-2.94) (182). Nevertheless, 
the role of CRP in the context of tumour promotion remains unclear. To present an overview of 
the association between serum CRP and breast cancer risk, a summary of epidemiological 
evidence linking prediagnostic CRP and incidence of breast cancer is shown in Table 1. Papers 
selected in this table were identified via PubMed literature searches conducted at the time this 
thesis was initiated and again in late August 2015. Searches were conducted using terms ‘C-
reactive protein’, ‘serum’ and ‘breast cancer’ and restricted to human studies and English 
language publications published up to and including August 2015. References from selected 
papers were hand-searched to include additional papers. 
 
Overall, the association between serum CRP and breast cancer risk remains conflicting, which 
aligns with results from a meta-analysis reporting a lack of association between baseline serum 
CRP and risk of breast cancer (183). Nevertheless, a recent case-cohort study showed an 
increased risk of breast cancer in postmenopausal women receiving hormonal therapy, but not 
those without (152), implying effect modification by hormonal factors. Although obesity has also 
been suggested to affect CRP levels (148), only one study showed adiposity status to modify the 
association between CRP and breast cancer risk (184). In the context of prognosis, there is 
evidence that higher postdiagnostic levels of CRP correspond to shorter progression-free and 
overall survivals of breast cancer patients (185). Given the correlation between CRP and other 
factors such as adiposity and external hormones (152, 184), it is essential to explore factors 




Table 1. Overview of epidemiological studies assessing the link between serum CRP and breast cancer incidence  




Risk of breast cancer Notes 
Il’yasova et al, 
2005 (186) 
The Health Aging and 
Body Composition 
Study; US; women 
aged 70-79 years 
Cohort 1,305 without cancer; 
mean follow-up 5.5 
years 
CRP ELISA HR: 1.32 (95% CI: 0.91-1.93) 
for every log CRP increase 
Adjusted for age, race, and site 
Siemes et al, 
2006 (187) 
 
The Rotterdam Study; 
Netherlands; women 
aged 55 years and over 
Cohort 3,307 without cancer, 






HR: 1.23 (95% CI: 1.02-1.50) 
for every log CRP increase 
Adjusted for age, smoking, 
body mass index, age at 
menarche and menopause, 
hormone use, and number of 
children 
 
Zhang et al, 
2007 (188) 
Women’s Health 
Study; US; female 
health professionals 
aged 45 and over 
Cohort 27,919 without cancer, 





HR: 1.02 (95% CI: 0.73-1.41)  
for highest vs lowest quintile; 
Ptrend 0.81 
Adjusted for age, intervention 
group, age at menarche, age at 
first pregnancy lasting ≥6 
months, number of 
pregnancies lasting ≥6 months, 
menopausal status, age at 
menopause, family history of 
breast cancer, history of benign 
breast disease, postmenopausal 
hormone use, BMI, physical 
activity, multivitamin 
supplement use, smoking 
status, and alcohol intake  
 
Allin et al, 2009 
(189) 
The Copenhagen City 
Heart Study, Denmark; 
women aged 20 and 
over 
Cohort 5,369 without cancer; 






HR: 0.9 (95% CI: 0.4-1.4) for 
highest vs lowest quintile; 
Ptrend = 0.79 
Adjusted for age at diagnosis, 
sex, cancer type, cancer stage, 
cancer histology, and time 
from blood sampling to 
diagnosis 
 
Heikkila et al, 
2009 (190) 
The British Women’s 
Heart and Health Study 
(BWHHS); UK; 
women aged 60-79 
years 
Cohort 3,274 without cancer hs-CRP 
nephelometry 
HR: 1.00 (95% CI: 0.76-1.31) 
for every log CRP increase; 
Ptrend = 0.90 
Adjusted for age, BMI, 
smoking, childhood and adult 
socioeconomic position, 





Note: NS = Not Specified; OR = odds ratio; HR = hazard ratio; 95% CI: 95% confidence intervals 




Risk of breast cancer Notes 
Van 
Hemelrijck 




Sweden; women aged 
20 and over 
Cohort 59,220 without cancer; 
mean follow-up  9.5 
years 
CRP turbidimetry HR: 0.76 (95% CI: 0.41-
1.43) for CRP > 50 
mg/L vs < 10 mg/L; 
Ptrend = 0.77  
Adjusted for age, 
socioeconomic status, and 






Risk in Communities 
(ARIC) study; US; 
women aged 45-64 
years 




HR: 1.27 (95% CI: 1.07-
1.51) for every log CRP 
increase 
Adjusted for age, center, 
education, BMI, waist, 
aspirin use, smoking status, 
hormone therapy use, 
menopausal status, age at 






The CPS-II Nutrition 
Cohort; US; women 
50-74 years 
Cohort  297 cases and 297 
controls; follow-up NS 
CRP ELISA OR: 1.09 (95% CI: 0.70-
1.70) for highest vs 
lowest tertile; Ptrend = 0.16 
Matched for age and race. 
Adjusted for time from last 
meal to blood draw, alcohol 
in the 24 hours before 
blood draw, prior diagnosis 
of diabetes, family history 
of breast cancer, and BMI 
Gunter et al, 
2015 (152) 












HR: 1.24 (95% CI: 0.86-
1.80) for highest vs 
lowest quartile;  Ptrend = 
0.12 
Adjusted for age, ethnicity, 
alcohol consumption, 
family history of breast 
cancer, parity, years of 
menstrual cycling, age at 
first child’s birth, use of 
hormone therapy, 
endogenous estradiol levels 
(in non-hormone therapy 
users only), history of 
benign breast disease, body 
mass index, physical activity 
49 
 
1.3.3. Underlying factors of inflammation and breast cancer 
As mentioned before, inflammation occurs in an array of conditions such as altered metabolic 
states and allergy, which will be discussed further in this thesis. An understanding into how these 
underlying factors of inflammation may affect breast cancer is therefore important in gaining 
further insight into this complex association. 
 
1.3.3.1. Allergy 
Accruing evidence has indicated that allergy may be associated with the development of cancer, 
although findings in breast cancer are scarce. Hypotheses linking allergy and cancer are mainly 
divided into two groups which suggest that 1) allergy may reduce cancer risk and 2) it may 
increase cancer risk. The first includes the immunosurveillance hypothesis, which states that 
increased immune surveillance following hyperreactive immune responses may further hinder the 
development of cancer (192). Similarly, the prophylaxis hypothesis suggests that physical effects 
of allergic symptoms may prevent cancer, such as the act of sneezing in the attempt to remove 
allergens from the airway tract (193). The opposing hypotheses include a shift in T-helper 
balance which determines the type of immune responses elicited. Predominance of TH2 over TH1 
underlies the hypersensitivity reactions in allergy, and is thought to divert immune responses 
from the tumour-eradicating TH1 counterpart (194). Additionally, allergy is also a state of chronic 
inflammation, which may lead to initiation and promotion of cancer (158). Considering the 
complex nature of this relationship, it is important to first clarify how allergy is associated with 
overall cancer in order to gain insight into its potential role in breast cancer development. 
 
Findings from observational studies studying allergy in relation to cancer risk remain hampered 
by the diverse methods used in assessing an individual to be ‘allergic’. In general, two strategies 
have been employed: using self-reported history of allergic disorders, which is the most widely 
used method, and conducting objective measurements of allergy (195, 196). Besides its high 
feasibility and low costs, an advantage of using self-reported history is its ability to represent 
clinically relevant or symptomatic allergy. However, assessment of allergy relies on an individual’s 
recall, and therefore may not correctly represent the state of allergy prior to cancer development. 
More importantly, different types of hypersensitivity reactions are underlain by different 
immunological mechanisms (139), which may be difficult to assess without any standardised 
objective assessment. Some studies utilising this method have shown a protective effect of 




As atopy or IgE-mediated hypersensitivity reactions comprise the majority of allergy (146),  
measurements of total IgE levels in serum may be used as an objective assessment. However, 
IgE is also involved in other immune-related mechanisms such as the defence against parasite 
infections (139), indicating a lack of specificity when using total IgE. A preferable alternative is 
to specifically assess IgE sensitisation to a particular antigen through allergy tests such as skin 
prick test and serum allergen-specific IgE. The sensitivity and specificity of both tests are 
considered to be comparable (199, 200), but serum specific IgE is considered more feasible and 
safe due to a risk of anaphylaxis which follows skin prick test (201, 202).  
 
Table 2 shows an overview of epidemiological evidence linking atopy, assessed with serum 
specific IgE, and cancer risk. Papers selected in this Table were identified via PubMed literature 
searches conducted at the time this thesis was initiated and again in late August 2015. Searches 
were conducted using terms ‘immunoglobulin E’, ‘serum’ and ‘cancer’ and restricted to human 
studies and English language publications published up to and including August 2015. 
References were hand-searched to include additional papers. 
 
Overall, findings comparing cancer risk associated with atopic and non-atopic individuals vary by 
cancer types. The most consistent association has been observed for brain cancer, where atopic 
individuals are suggested to have a lower risk compared to non-atopic subjects (203–206). For 
breast cancer, a lack of association has been observed, which is similar to results from a meta-
analysis assessing atopy diagnosed by skin prick test in relation to breast cancer (195), and 
findings using total serum IgE (196). Nevertheless, it should be noted that the skin prick test and 
specific serum IgE, despite their superiority to total IgE, only reflect IgE sensitisation, which is 
not always followed by clinical allergy (199, 200).  
 
Recently, it has been suggested that the proportion of serum specific IgE among total IgE may 
better reflect clinical manifestation of atopy (207), but its importance with regards to cancer risk 
is yet to be reported. Additionally, all previous studies dichotomised results from specific IgE 
test into ‘positive’ and ‘negative’ in order to assign an individual to be atopic or non-atopic, and a 
loss of information may occur should there be a threshold of IgE levels which indicate specific 
immune responses associated with the susceptibility of developing cancer. Assessment of results 
from serum specific IgE assessment with respect to cancer risk in a dose-dependent manner, 




Table 2. Overview of epidemiological studies assessing the link between serum specific IgE and cancer incidence 





Outcome Risk of cancer (95% 
confidence intervals) 
Notes 
Wang et al, 
2006 (14) 
The ‘Epidemiologische 





Erkrankungen in der 
älteren Bevölkerung’ 
(ESTHER) , Germany, 




478 colorectal, 197 
lung, 320 prostate 
and 381 female 
breast cancer cases 
and 4,271 controls 
Serum specific IgE 











OR: 1.35 (1.00-1.83) for 
positive vs negative 
 
OR: 1.20 (0.87-1.66) 
OR: 1.29 (0.87-1.92) 
 
OR: 1.03 (0.80-1.34) 
Adjusted for age, 
gender (except for 
prostate and breast 
cancer), education 
BMI, family history 




et al, 2007 
(208)                                                





467 lymphoma and 
544 controls 
Serum specific IgE 
to inhalant allergens 
panels – Immulite 
2000 (positive, 
negative) 
Lymphoma OR: 0.67 (0.45-1.00) for 
positive vs negative 
Matched on age, 
sex, centre 
Adjusted for age, 
sex, centre, 
smoking, treated 
asthma or eczema 





Study, Denmark and 
Sweden, aged 18-74 
 
 












2670 NHL cases 






198 NHL cases and 
594 controls 
Serum specific IgE 
to inhalant allergens 
– Phadiatop 
(positive, negative) 
NHL OR: 0.68 (0.58-0.80) for 






OR: 0.74 (0.48-1.15) 
Matched on age, 
sex, country 
Adjusted for age, 




Matched on age, 




Greece, women  Case 
control 
103 female breast 
cancer cases, 103 
controls 
Serum specific IgE 






Breast cancer OR: 1.73 (0.95-3.14)  Matched on age 
Adjusted for age, 
education, height, 
BMI, age at 
menarche, parity, 









Outcome Risk of cancer (95% 
confidence intervals) 
Notes 
Calboli et al, 
2011(205) 
The Physicians’ 
Health Study (PHS), the 
Nurses’ Health Study 
(NHS), the 
Women’s Health Study 
(WHS), and the Health 
Professionals 
Follow-Up Study 
(HPFS), U.S., men and 




181 glioma cases 
and 542 controls 











OR: 1.03 (0.54-1.98) 
Matched on year of 
birth, cohort, sex, 
intervention (in the 






into Cancer and 
Nutrition (EPIC), 





696 brain tumour 
cases and 1188 
controls 
Serum specific IgE 









OR: 0.53 (0.30-0.95) in 
women 
OR: 0.89 (0.55-1.45) in men 
OR: 1.15 (0.65-2.02) in 
women 
OR: 0.64 (0.26-1.54) in men 
OR: 0.80 (0.32-1.99) 
Matched on centre, 
sex, date of birth, 
age, data of 
sampling, time of 





m et al, 2012 
(203) 
The Janus Serum Bank 
project, Norway, men 




594 glioma cases 
and 1177 controls 
Serum specific IgE 
to inhalant allergens 
– ImmunoCAP 
(positive, negative) 
Glioma OR: 0.46 (0.23-0.93) for 
positive vs negative in 
women 
OR: 1.02 (0.72-1.44) for 
positive vs negative in men 
Matched on age 
interval, sex, 
sampling date 




into Cancer and 
Nutrition (EPIC), 







and 1,021 controls 
Serum specific IgE 
to inhalant allergens 




OR: 0.98 (0.77-1.23) for 
positive vs negative 
 
Matched on centre, 
sex, blood donor 
status, age, date and 
time of sampling 
Adjusted for 
education, smoking 
Olson et al, 
2014 (212) 
The Prostate, Lung, 
Colorectal, and Ovarian 
Cancer Screening Trial 






cancer cases and 544 
controls 








OR: 2.83 (1.29-6.20) for 
positive vs negative IgE to 
food allergen in age 65+; 
OR < 1 in age < 65 
 
No association with inhalant 
allergens 
Matching on age, 
gender, race, 













Outcome Risk of cancer (95% 
confidence intervals) 
Notes 
Skaaby et al, 
2014 (213) 
Denmark; men and 
women 
Cohort  14,849 without 
cancer; median 
follow-up 11.8 years 
















HR: 1.00 (0.89-1.12) for 
positive vs negative  
 
HR: 1.74 (0.98-3.09) 
HR: 0.92 (0.64-1.32) 
HR: 0.78 (0.54-1.13) 
 
HR: 1.00 (0.73-1.37) 
HR: 0.79 (0.53-1.18) 
HR: 1.08 (0.60-1.96) 
HR: 0.95 (0.54-1.66) 
HR: 1.20 (0.98-1.47) 
Age as timescale 






Note: HR = hazard ratio; OR = odds ratio
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1.3.3.2. Metabolic disorders  
There has been an emerging interest in how metabolic processes may be implicated in cancer 
progression. Two views have been generally accepted: cancer itself may manipulate cellular 
metabolism in its favour, and secondly, systemic metabolic states may also affect the clinical 
course of the disease. Using examples from these two perspectives, the following section 
discusses two common metabolic alterations which have been associated with both inflammation 
and breast cancer. 
 
The Warburg effect 
Among various metabolic abnormalities accompanying the development of cancer, one of the 
most important is altered cellular metabolism of energy and glucose (13). In normal cells, when 
oxygen is available, pyruvate generated during the breakdown of glucose is utilised to produce 
energy through oxidative phosphorylation. In contrast, tumour cells prefer pyruvate metabolism 
via anaerobic pathway regardless of oxygen availability, leading to inefficient fuel production and 
formation of lactate. This anomalous metabolic preference is called the Warburg effect or 
‘aerobic glycolysis’ (214, 215). Aerobic glycolysis is also known to be closely related to 
inflammation. Activation of macrophages and T-helper cells leads to a metabolic shift to aerobic 
glycolysis (216), and correspondingly, a negative feedback of inflammation is provided by 
glycolytic products (217). In cancer cells, a positive regulation of aerobic glycolysis by pro-
inflammatory cytokines such as TNF-α has also been documented (218, 219). However, it is 
suggested that chronic hypoxia secondary to tumour growth activates a feed-forward stimulatory 
loop between hypoxia pathways and aerobic glycolysis (220, 221), resulting in persistently altered 
metabolic states. Additionally, hypoxia induces endoplasmic reticulum stress in growing tumours 
(222, 223). As endoplasmic reticulum stress leads to accumulation of oxidative stress and 
activation of pro-inflammatory responses (224), it follows that a synergistic activation of aerobic 
glycolysis and inflammation may take place in malignancy, which may impact cancer progression. 
 
A widely known marker for aerobic glycolysis is lactate dehydrogenase (LDH), which is the 
enzyme responsible for the conversion of pyruvate to lactate during glycolysis (225). LDH A and 
B subunits, coded by two different genes LDH-A and LDH-B, combine to construct five 
isoenzymes (LDH1 to LDH5) with selective distribution among tissues and in serum (226). The 
use of protein and gene expression of LDH has provided further insight into the role of aerobic 
glycolysis in cancer. For instance, in breast cancer, higher expression of LDH-A is observed in 
HER2-positive compared to HER2-negative cells, which indicates that the extent of glycolysis 
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varies across different subtypes (227). Moreover, an effect on breast cancer therapy has been 
indicated, as targeting LDH-A in combination with trastuzumab is able to inhibit trastuzumab-
resistant breast cancer in experimental models (228). In the context of prognosis, a role for 
circulating levels of LDH has been suggested. Serum LDH is one of the five risk factors included 
in the International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL) (229, 
230), and a similar association is suggested in other cancer types such as lung (231–233) and 
haematological malignancies (234, 235). One study reported an association with breast cancer, 
where lower overall survival followed higher LDH levels among patients with bone metastases 
(HR: 4.50, 95% CI: 2.27-8.94) (236). Nevertheless, studies investigating the role of LDH in 
cancer survival were mostly performed in clinical trial settings where only patients with advanced 
disease were included, thereby limiting the generalisation of the current findings. Additionally, 
these studies focused on overall rather than cancer-specific survival, as reflected in a recent meta-
analysis on LDH and survival in solid tumours where no studies reported cancer-specific survival 
as an outcome (237). Moreover, marked publication bias has been noted in this review. As serum 
LDH is also known to be increased in tissue injury, inflammation, haemolysis and myocardial 
infarction (238–240), it is necessary to confirm any association between serum LDH and cancer-
specific death, and to assess whether such an association exists for breast cancer. 
 
Altered glucose and lipid metabolisms 
Disorders in glucose and lipid metabolism have been suggested as a mechanism linking obesity 
and breast cancer development (241, 242). In addition to their roles in carcinogenesis, increasing 
evidence suggests that abnormal levels of serum glucose and lipids impact survival in breast 
cancer patients (243–245). The mechanism through which glucose and lipid metabolisms may 
affect cancer progression is not clear, although a role of chronic inflammation is likely to play 
part. For instance, in obese individuals, increased adiposity is associated with increased 
production of cytokines including TNF-α, IL-6, and IL-1 (246). Apart from their correlation 
with obesity, abnormal levels of circulating glucose and lipids may also induce systemic 
inflammation, which may impact patient survival (185). Elevated serum glucose is thought to 
promote chronic inflammation through the generation of advanced glycation end products 
(AGEs), a product of non-enzymatic glycation of free amino group of proteins, lipids, or amino 
acids (247, 248). Similarly, serum lipids may contribute to inflammation through generation of 
lipid peroxides (249, 250). Furthermore, elevated levels of low-density lipoprotein cholesterol 
(LDL-C) as well as reduced levels of high-density lipoprotein cholesterol (HDL-C) have been 
linked to an increased activity of pro-inflammatory markers such as TNF-α and IL-6 (251, 252). 
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Both serum glucose and lipids are also linked to insulin resistance, which is signified by a 
compensatory production of insulin (253, 254) accompanied by an increase production of 
insulin-like growth factor I (IGF-I) (255). Insulin and IGF-I are known as strong growth factors 
(255), and have been implicated in breast cancer metastasis (256, 257). Additionally, insulin and 
IGF-I stimulate estradiol and testosterone production (258) further promote inflammation (259). 
All this evidence denotes the intricate network involving metabolic pathways and inflammation 
which may be important in breast cancer progression. 
 
Studies linking serum glucose and lipids with breast cancer survival have yielded inconclusive 
results (243–245). A possible cause of this unclear link is the strong association between levels of 
glucose and lipid components such as triglycerides and total cholesterol with cardiovascular 
disease, which is the most common cause of death in the general population (260, 261). This 
common relationship may be explained by shared metabolic pathways including chronic 
inflammation and insulin resistance, both of which may drive formation of atherosclerotic plaque 
in addition to their aforementioned effects on cancer cells (242, 262, 263). Such risk correlations 
may thus result in a competing risk situation (264), where individuals with similar sets of risk 
factors are at risk of dying from both breast cancer and cardiovascular disease. To date, there is 
limited evidence on how competing risks affect the association between systemic glucose and 
lipid metabolisms and breast cancer survival. More investigations in this subject are thus needed 















1.4. Aims and Objectives 
Breast cancer is a complex health problem which necessitates a multidimensional approach in 
order to reduce the burden it imposes. Several points formed the basis of research conducted 
within this thesis. First, despite a dramatic expansion of breast cancer characterisation in the last 
few decades, there is still a lack of understanding in the aetiology of most breast cancer cases, 
especially in patients without well-known genetic susceptibility. Secondly, although lifestyle has 
increasingly been linked to cancer and may provide opportunities for primary prevention, precise 
mechanisms leading to breast cancer development and progression remain unclear. Finally, 
current literature provides little evidence on whether there is any impact of other co-morbidities 
when assessing specific markers in relation to breast cancer survival. With longer life expectancy 
that follows advancement in medical treatment, there is an urge to study the complexity of 
survival determinants beyond cancer diagnosis in which other diseases are taken into 
consideration.  
 
To address some of the aforementioned concerns, this thesis sought to investigate whether 
inflammation and associated underlying disorders are implicated in breast cancer development 
and progression. More specifically, this thesis had the following objectives: 
 
1. To study the role of inflammation in the development of breast cancer by assessing 
serum CRP, albumin, haptoglobin and WBC in relation to breast cancer risk, severity at 
diagnosis and survival. 
 
2. To evaluate any association between atopy and cancer risk using serum specific IgE 
against inhalant allergens and serum total IgE, with an emphasis on breast cancer. 
 
3. To investigate the impact of prediagnostic serum lactate dehydrogenase on overall and 
cancer-specific survival following diagnosis and identify whether such associations differ 
with respect to tumour characteristics in breast cancer.  
 
4. To assess the link between prediagnostic serum glucose, triglycerides, total cholesterol 







Figure 12. Schematic representation of research questions 
 
Figure 12 graphically summarises the research questions posed in this thesis with relation to the 
plausible pathways linking inflammation, relevant clinical markers, and breast cancer. Through 
more understanding into the role of inflammation, its clinical markers and underlying factors in 
breast cancer, this thesis provides support for further mechanistic and clinical research utilising 
inflammatory markers in predicting breast cancer outcomes. Eventually, such findings are 
expected to contribute to shed light to the aetiology of breast cancer and its implications on 


















































Chapter 2: Methods 
To allow clear description of research methods undertaken within the scope of this thesis, this 
section firstly explains the population in which analyses within this thesis were conducted and 
the source where data was obtained from. This is followed by explanations of specific methods 
to address each research question individually. 
 
2.1. The Apolipoprotein Mortality Risk Study (AMORIS)  
AMORIS is a large Swedish database containing 812,073 Swedish men and women, ranging in 
age from < 20 to 80 years-old and over. This cohort is based on a linkage between data from 
laboratory examinations performed in the Central Automation Laboratory (CALAB) in Sweden 
and information recorded in various Swedish National Registers using a 10-digit personal 
identifier number which is unique to every Swedish resident (265). As a result, AMORIS is 
currently one of the largest prospective cohorts containing information on serum biomarkers, 
cancer diagnosis, co-morbidities, vital status, socioeconomic status, and emigration (Please see 
Appendix 1.1. for an overview of published studies from The AMORIS cohort). This study 
complied with the Declaration of Helsinki and was approved by the Ethics Review Board of the 
Karolinska Institute.  To understand the scope of AMORIS in this thesis, the linkages of the 
different data sources used in this cohort as well as the information available within each of them 
are further explained below. 
 
2.1.1. Central Automation Laboratory (CALAB) database 
CALAB was a major laboratory in Stockholm, Sweden, that served more than 3,000 physicians 
in the Swedish healthcare system. This laboratory was acknowledged for Good Laboratory 
Practice and internationally accredited in clinical chemistry, hematology, immunology, and 
microbiology (266). Participants of the AMORIS Study comprised Swedish residents whose 
blood samples were collected and examined in the CALAB between 1985 and 1996, and were 
mostly (67%) residents of the Stockholm County at the time of sample collection. These 
individuals were either healthy and had laboratory tests as a part of general check-up, or were 
outpatients referred for laboratory tests. None of the participants were inpatients at the time the 
samples were analysed. No clinical data were included in the CALAB database apart from 
information on blood test results and date of examination, participant age, sex, date of birth, and 
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personal identifier number, the latter of which was used to link the database to a number of 
Swedish National Registers in AMORIS.  
 
2.1.2. Swedish National Registers 
A personal identifier number, which has been established since 1947, allows data linkage 
amongst different national registers in Sweden (267). Swedish register linkages are mainly 
handled by two government agencies: the National Board of Health and Welfare and Statistics 
Sweden. The National Board of Health and Welfare is a government agency under the Ministry 
of Health and Social Affairs which is responsible for maintenance of health data registers and 
official statistics (268). This agency has a very wide range of activities and many different duties 
within the fields of social services, health and medical services, environmental health, 
communicable disease prevention and epidemiology. In addition to data maintenance, the agency 
also collects, compiles, analyses and passes on information related to the above fields, as well as 
developing standards based on legislation and the information collected. The second agency, 
Statistics Sweden, is an administrative agency with the main task of supplying both public and 
private customers with statistics for decision making, debate and research (269). This agency also 
supports and coordinates the system used for official statistics and publishes the vital statistics of 
Sweden, which are updated daily regarding births, migrations, deaths, and marital status. Register 
maintenance and linkages in health care often simultaneously involve both agencies, and have 
enabled feasible and efficient evaluation of Swedish health care, as well as data utilisation for 
large-scale medical research.  National registers linked within the scope of AMORIS are shown 
in Figure 13 and further described in the following sections. 
 
 




2.1.2.1. National Cancer Register 
The Swedish Cancer Register, maintained by the National Board of Health and Welfare, was 
founded in 1958 and covers the whole population (268). It is compulsory for every health care 
provider to report newly detected cancer cases to the registry.  A report has to be sent for every 
cancer case diagnosed at clinical, morphological, and other laboratory examinations as well as 
cases diagnosed at autopsy. Three types of data are available: patient demographics (personal 
identification number, sex and place of residence), medical data (site of tumour, date of 
diagnosis, histological type, tumour stage), and follow-up data (date and cause of death and 
date of migration). Cancer sites are coded according to the international (English) version of the 
Seventh Revision of the International Classification of Diseases (ICD-7) (Table 3). For medical 
data, information on histological type was collected since 1993 and tumour stage since 2004. 
Since the mid-80’s, there are six regional registries associated with the oncological centres in each 
medical region of Sweden where the registration, coding and major check-up and correction 
work is performed. This regionalization implies a close contact between the registry and the 
reporting physician, which in turn simplifies the task of correcting and checking the material. 
The regional registries send information about newly registered cases and correction concerning 
those previously reported to the National Cancer Register on an annual basis. Underreporting of 
cancer cases in the Register was estimated to be 3.7% based on a comparison against the 
population-based Hospital Discharge Register in 1998 (270), and was highest among elderly (70+ 
years). In a more recent investigation, a comparison between the 2009 National Palliative Care 
Register with data from the National Cancer Register from 1958 to 2009 showed that 12.5% 
cases of cancer death were not reported to the National Cancer Register (271). However, this 
figure only represented underreporting in patients who received end-of-life care, and was likely 
to be lacking generalisability to the Swedish population as a whole.  
 
2.1.2.2. Cause of Death Register 
Since 1953, the Cause of Death Register has been overseen by the National Board of Health and 
Welfare as a database containing the time and cause of death of Swedish residents. 
Information on all those died during one calendar year and were registered in Sweden at the time 
of death was collected, regardless of whether the death occurred in Sweden or abroad. The 
causes of death are coded centrally at Statistics Sweden according to the international (English) 
version of the Eighth, Ninth and Tenth Revision of the ICD (ICD-8, ICD-9 and ICD-10) (Table 




Table 3. International classification of diseases (ICD) codes used in AMORIS to classify cancer site 
Cancer site ICD-7 ICD-8 ICD-9 ICD-10 
All cancer 140-207 140-209 140-208 C00-C97 
Breast 170 174 174 C50 
Prostate 177 185 185 C61 
Pulmonary (primary) 162 162 162 C33, C34 





Gastroesophageal 150, 151 150, 151 150, 151 C15-C16 
Hepatobiliary (primary) 155 155, 156 155, 156 C22-C24 
Pancreas 157 157 157 C25 
Kidney  180 189.0, 189.1 189.0, 189.1 C64, C65 
Bladder 181 188 188 C67 
Gynecological 171-176 180-184 179-184 C51-C58 








Melanoma 190 172 172 C43 
NMSC 191 173 173 C44 
Central nervous system (CNS) 193 191, 192 191, 192 C70-C72 
Thyroid 194 193 193 C73 
Haematological 200-207 200-209 200-208 C81-C96 
NMSC = Nonmelanoma skin cancer 
 
2.1.2.3. Hospital Discharge Register 
The Hospital Discharge Register was established by the National Board of Health and Welfare as 
part of the National Patient Register in 1964 and has had complete national coverage since 1987 
(273). This Register contains data on patients (personal identification number, sex, place of 
residence), hospital identification, administrative data (date of admission and discharge, 
acute/planned admission) and medical data (main and secondary discharge diagnoses and major 
interventions), which enable assessments of history of other diseases or co-morbidities. The 
above information is delivered to the Centre for Epidemiology (EpC) at the National Board of 
Health and Welfare from each of the 21 county councils in Sweden and is updated once a year 
(268). Every discharge corresponds to one record in the Register. In 2006, the completeness of 
discharge data was 99.4% for personal identifier number and 99% for the main diagnosis. A low 
number of drop-out has also been recorded, with an estimated rate of less than one percent in 
2007.  
 
2.1.2.4. Total Population Register 
In 1968, Statistics Sweden established the Total Population Register, which contains information 
about the people that live in Sweden and about where in the country they reside (274). This 
Register is presently managed by the Swedish Tax Agency and contains information on names, 
personal identifier number, residence, birth place, immigration and emigration including 
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addresses abroad (275). If registered for the first time, a person will receive a personal identifier 
number which will be used in subsequent official administration in Sweden afterwards. From 
1970 to 1990, the Total Population Register conducted a five-yearly Population and Housing 
Census, which collected information from questionnaires and nationwide registries including 
data on demographics, occupation and earnings. Information on occupation and earnings was 
used to create a variable for socioeconomic status which classifies gainfully employed subjects 
into manual and non-manual workers, designated as blue-collar and white-collar workers (266). 
 
2.1.2.5. Multi-generation Register 
The first census in Sweden took place in 1961 and was later used to serve as a basis for the 
Multi-generation Register which also utilises personal identifier number (274). This database 
contains parentage information including personal identifier number of an individual and their 
biological (and adoptive) parents, date and place of birth, number of children, and date of 
immigration. In 2005, information on mother was found in 97% and on father was found in 
95% of total individuals born in Sweden that year. The equivalent frequencies of those born 
outside Sweden are 27% and 22%, respectively. Lower frequencies are present for mothers and 
fathers of those born during the 1930s, which align to the introduction of the personal identifier 
number in January 1, 1947. Therefore, information on biological mothers is available in 98% of 
individuals born in 1947 and 100% of those born in 1961 and onwards. The equivalent numbers 
for fathers are 94% for those born in 1947 and 98% for those born in 1961 and onwards.  
 
2.1.2.6. Breast Cancer Clinical Quality Register 
The Breast Cancer Clinical Quality Register contains detailed information regarding breast cancer 
tumour characteristics. In the AMORIS Study, a linkage in 2014 to the Stockholm Regional 
Breast Cancer Clinical Quality Register provided data from 1985 onwards on breast cancer 
tumour characteristics at diagnosis including tumour size, nodal status and distant metastasis 
which were used to classify tumours by TNM stage according to the American Joint Committee 
on Cancer (AJCC) Cancer Staging Manual, 7th edition. In some patients, further information on 
grade, receptor status (ER, PR and HER2), and menopausal status were available. The 
follow up of AMORIS participants relative to this quality register and the National Cancer 





Figure 14. Follow-up of cancer incidence based on national and regional registers 
 
2.2. Data Collection and Analysis 
Although all studies within this thesis were based on the AMORIS population, different methods 
were employed to address different questions as previously described. Therefore, the following 
section is divided into four parts, each corresponding to specific data collection and analytical 
techniques conducted for each research question.  
 
2.2.1. Systemic inflammatory markers in relation to breast cancer risk, severity, and 
survival 
2.2.1.1. Study population 
This study investigated the associations of serum markers of inflammation with risk of breast 
cancer, disease severity, and survival following diagnosis (Please see Appendix 1.2. for 
publication of this study). We selected all women aged 20 and older with baseline serum CRP 
and albumin from the AMORIS population (N=155,179) (Figure 15), among which 6,606 
developed breast cancer during follow-up. All participants with any prior history of cancer at 
baseline were excluded. To exclude reverse causation, only women with follow-up time of more 
than 2 years were deemed eligible. Among this population, 149,258 women who had at least 15 
of any biomarkers at CALAB, which represented general health check-up, showed similar 
characteristics to the main study population. Therefore, analyses were conducted on the full 







2.2.1.2. Exposure and outcome assessments 
Serum CRP (mg/L), albumin (g/L), haptoglobin (g/L) and WBC (10 x 109/L) were measured at 
baseline with standard laboratory methods as detailed in Table 4. High sensitive CRP (hsCRP) 
was not available at any time in the period of blood sample collection (1985-1996), so that CRP 
concentrations <10 mg/L could not be measured precisely (266). However, this cut-off point of 
10 mg/L is widely accepted as the upper limit of the health-associated reference range (276) and 
was therefore used in this study. Levels of serum inflammatory markers were assessed as high or 
low based on their clinical cut-offs used in CALAB: CRP 10 mg/L, haptoglobin 1.4 g/L, and 
WBC 10 x 109/L. For albumin, a cut-off point of 40 g/L was used instead of 35 g/L due to the 
small number of participants with low albumin levels. 
 
In addition to serum inflammatory markers, the following baseline information was obtained 
from AMORIS: socioeconomic status (white collar, blue collar, unemployed or unknown), parity 
(nulliparous, 1+ children), history of hospitalisation for liver disease, rheumatic disease, diabetes 
and lung disease (ever, never).  
 
AMORIS 
(N = 812,073) 
Women aged 20+ 
Baseline measurements of 
CRP and albumin  
(N = 155,179) 
Additional baseline 
measurements of WBC 
 





(N = 100,903) 
 
Figure 15. Overview of study population 
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There were three outcomes investigated in this study: breast cancer diagnosis, breast cancer 
severity, and breast cancer survival. A severity classification which was a modified version of the 
conventional St. Gallen criteria was used (277), and breast cancer cases were categorised into 
three levels of severity: mild, moderate, and severe based on information on age at diagnosis, 
tumour stage, and ER status (Table 5). When investigating breast-cancer survival, both breast 






Table 4. Laboratory methods used to measure selected serum markers in CALAB 
Marker Instrument Method Total 
imprecision 
CRP AutoChemist PRISMA (New Clinicon, 
Bromma, Sweden) 1985-1992 and 
Technicon DAXTM 96 Multichannel 
Analyzer (Bayer Diagnostics, Tarrytown, 
USA) 1993-1996 
Immunoturbidimetry 




Albumin AutoChemist PRISMA (New Clinicon, 
Bromma, Sweden) 1985-1992 and 
Technicon DAXTM 96 Multichannel 





Haptoglobin Hitachi 911 Automatic Analyzer 
(Boehringer Mannheim, Germany) 
Immunoturbidimetry 
using reagents from 
Orion Diagnostics 
(Helsinki, Finland) 
 5.6% CV 
WBC Coulter STKS Haematology System 
(Coulter Corporation, Hialeah, USA) 




blood cell counting 
from whole blood 
samples 
<2.7% CV 
Specific IgE Pharmacia CAP  System (Thermo Fisher 
Scientific, formerly Pharmacia Diagnostics 
AB, Uppsala, Sweden) 
Immunoassay 10.0% CV 
Total IgE Immunoassay System ES 700 (Boehringer-





LDH AutoChemist PRISMA (New Clinicon, 
Bromma, Sweden) 1985-1992 and 
Technicon DAXTM 96 Multichannel 





Glucose AutoChemist PRISMA (New Clinicon, 
Bromma, Sweden) 1985-1992 and 
Technicon DAXTM 96 Multichannel 





Triglycerides AutoChemist PRISMA (New Clinicon, 
Bromma, Sweden) 1985-1992 and 
Technicon DAXTM 96 Multichannel 







AutoChemist PRISMA (New Clinicon, 
Bromma, Sweden) 1985-1992 and 
Technicon DAXTM 96 Multichannel 










Table 5. Severity classification of breast cancer at diagnosis 
Mild Moderate Severe 




TNM Stage I 




TNM Stage II 








TNM Stage III or IV 
 
2.2.1.3. Statistical analysis 
First, risk of breast cancer based on different levels of baseline serum inflammatory markers was 
assessed. Follow-up time was defined as the time from baseline measurements until date of 
breast cancer diagnosis, death from any cause, emigration, or end of study, whichever occurred 
first. Hazard ratios and confidence intervals for incident breast cancer were obtained with Cox 
proportional hazards regression, comparing women with high to low levels of CRP, albumin, 
haptoglobin and WBC. The assumption of proportional hazards was met by assigning variables 
as time-varying covariates. All models were adjusted for age at baseline measurements, 
socioeconomic status, and parity in individual analyses and a fully adjusted model. In addition to 
being included as a continuous variable, age was also adjusted as categories (<30, 30-40, 40-50, 
50-60, 60-70, 70 years and older). Additional adjustments were performed for diabetes and lung 
disease as a proxy for smoking. A sub-analysis based on menopausal status at baseline used age 
as a proxy of menopause. We conducted stratification analysis by menopausal status using two 
approaches. In addition to simple stratification analysis using age of 50 years as a proxy, we 
performed truncation analysis in which premenopausal women were followed to age 50 after 
which they were censored. In the assessment of postmenopausal risk, individuals with 
measurements before age 50 entered the study at age 50 by means of delayed entry. This 
approach including truncation analysis has previously been used in studies combining two 
populations in which reaching a certain age or menopause was a condition to enter the study 
(278). Since obesity is linked to inflammation and breast cancer (109, 148), analysis was repeated 
in the subgroup of women with baseline BMI while adjusting for BMI. Additionally, since 
disease of the liver may impair production of CRP, albumin and haptoglobin (279, 280), a 
sensitivity analysis excluding 521 women with history of liver disease was performed. A similar 
sensitivity analysis was performed by excluding 1,436 women with history of rheumatic disease 
since levels of CRP and haptoglobin may be influenced by the disease and its medications (281). 
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To assess the association between prediagnostic inflammatory markers and breast cancer 
severity, ordered logistic regression was used to estimate proportional odds ratios of more severe 
breast cancer by categories of CRP, albumin, haptoglobin and WBC. This analysis allowed the 
use of three severity categories as ordered outcomes and was performed in 5,108 breast cancer 
patients with available information on disease severity. The proportional odds assumption was 
met for all markers. The models were adjusted for age and menopausal status at diagnosis, period 
of diagnosis and interval time between baseline measurements and breast cancer diagnosis.  
 
Finally, inflammatory markers were investigated in relation to all-cause and breast cancer-specific 
death in 6,606 women with breast cancer. Patients were followed up until death, emigration or 
end of study, whichever occurred first. Cox proportional hazards models were used, adjusting 
for age and menopausal status at diagnosis, tumour stage, ER status, period of diagnosis, and 
interval time between baseline measurements and breast cancer diagnosis. Missing variables were 
assigned as a different value for menopausal status (18%), tumour stage (18%) and ER status 
(32%). To further illustrate this association, cumulative incidence functions for all-cause and 
breast cancer-specific death were displayed by categories of CRP, albumin, haptoglobin and 
WBC. Gray’s test for equality of cumulative incidence functions was performed to assess 
differences in cumulative risk of death with respect to baseline markers. 
 
All analyses were conducted with Statistical Analysis Systems (SAS) release 9.4 (SAS Institute, 














2.2.2. Atopy and cancer 
2.2.2.1. Study population 
To study the associations of atopy with cancer in general (Please see Appendix 1.3 and 1.4 for 
publication of this study), and more specifically with breast cancer, a total of 8,727 men and 
women aged 20 or above were selected among the AMORIS participants. All included 
participants had serum specific IgE test for inhalant allergens and total IgE measured in CALAB 
between 1992 and 1996 and no history of cancer at baseline measurements. 
 
2.2.2.2. Exposure and outcome assessments 
Serum levels of IgE against common inhalant allergens were measured using an immunoassay 
(Table 4). Results of allergen-specific IgE test were expressed as scores ranging from 0 to 6 
which represent different levels of IgE from undetectable up to high concentrations of IgE 
(kU/L) as displayed in Table 6. Inhalant allergens tested in this study are presented in Table 7. 
Apart from the IgE scores, no information on continuous levels of specific IgE was available. As 
with previous studies, any scores higher than 0 (which correspond to specific IgE levels of ≥0.35 
kU/L) were defined as IgE sensitisation and the presence of atopy (282). When multiple 
allergens were tested at baseline, results for all specific IgE measurements were collected. Atopy 
was defined as having at least one positive result among all the tested allergens. In addition to 
atopy status, highest specific IgE scores recorded at baseline examinations were considered as 
the exposure in this study.  
 
Table 6. Specific IgE scores in CALAB and corresponding serum concentrations 
Specific IgE score Serum concentrations (kU/L) Serum IgE levels 
0 <0.35 Absent/undetectable 
1 0.35 – 0.70 Low level 
2 0.70 – 3.50 Moderate level 
3 3.50 – 17.5 High level 
4 17.5 – 50 Very high level 
5 50 – 100 Very high level 









Table 7. Description of specific IgE against inhalant allergens tested in AMORIS 
CAP code Allergen-specific IgE  
D1 House dust: Dermatophagoides pteronyssinus IgE  
D2 House dust: 
Dermatophagoides farinae IgE  
D3 Mites: Dermamophagoides microceras IgE  
D70 Mites: 
 Acarus siro IgE  
D71 Mites: 
Lepidoglyphus destructor IgE 
D72 Mites: 
Tyrophagus putresentiae IgE 
D73 Mites: 
Glycyphagus domesticus IgE 
D74 Mites: 
Euroglyphus maynei IgE 
E1 Cat dander IgE 
E3 Horse dander IgE 
E4 Cow dander IgE 
E5 Dog dander IgE 
E6 Guinea pig epithelium IgE 
E70 Goose feathers IgE 
E78 Parrot (budgerigar) feathers IgE 
E82 Rabbit epithelium IgE 
E84 Hamster epithelium IgE 
E85 Chicken feathers IgE 
E86 Duck feathers IgE 
E87 Rat IgE 
E89 Turkey feathers IgE 
G1 Grass pollen: Sweet vernal IgE 
G12 Grass pollen: Cultivated rye EgE 
G13 Grass pollen: Velvet grass IgE 
G5 Grass pollen: Perennial rye-grass IgE 
G6 Grass pollen: Timothy grass IgE 
G7 Grass pollen: Common reed IgE 
H1 House dust IgE 
H2 House dust, Hollister-Stier Labs IgE 
M1 Molds/yeast: Penicillium notatum IgE 
M2 Molds/yeast: Cladosporium herbarum IgE 
M3 Molds/yeast: Aspergillus fumigatus IgE 
M6 Molds/yeast: Alternaria tenuis IgE 
T12 Tree pollen: Willow IgE 
T14 Tree pollen: Cottonwood IgE 
T2 Tree pollen: Grey alder IgE 
T3 Tree pollen: Common silver birch IgE 
T4 Tree pollen: Hazel IgE 
T7 Tree pollen: Oak IgE 
T8 Tree pollen: Elm IgE 
T9 Tree pollen: Olive IgE 
Tx5 Tree pollen mix IgE 
Tx9 Tree pollen mix IgE 
W10 Weed/flower pollen: Lambs quarters, Goosefoot 
IgE 
W12 Weed/flower pollen: Golden rod IgE 
W19 Weed/flower pollen: Wall Pellitory (P. Officinalis) IgE 
W20 Weed/flower pollen: Nettle IgE 
W6 Weed/flower pollen: Mugwort IgE 
W7 Weed/flower pollen: Marguerite, ox-eye daisy IgE 
W8 Weed/flower pollen: Dandelion IgE 
W9 Weed/flower pollen: English plantain, ribwort IgE 
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Besides serum specific IgE, measurements of total serum IgE (Table 3) were collected in 8,727 
participants. Total IgE levels were categorised based on its clinical cut-off points into low (< 25 
kU/L), moderate (25-100 kU/L) or high levels (≥100 kU/L) (196). Other information included 
in this study was age at baseline measurement (years), sex (male, female), socioeconomic status 
(white collar, blue collar, unemployed or unknown), and history of hospitalisation with chronic 
pulmonary disease including asthma (ever, never). Additionally, period of measurement was 
categorised (1992-1993, 1994-1995, 1996) to account for a long recruitment period. 
 
Diagnosis of incident cancer was the main outcome of interest in this study. Apart from overall 
cancer, all cancers excluding nonmelanoma skin cancer (NMSC) were assessed given the 
suggested underreporting of NMSC in European countries (283). Furthermore,  the ten major 
cancer sites in the study population were also evaluated: prostate, female breast, colorectal, 
gynaecological, haematological, melanoma, pulmonary, bladder, NMSC, central nervous system, 
and kidney cancer. The secondary outcomes of this study were all-cause and cancer-specific 
deaths. 
 
2.2.2.3. Statistical analysis 
Multivariable Cox regression was used to estimate hazard ratios (HR) with corresponding 95% 
confidence intervals (CI) of overall risk of cancer by atopy status (yes, no) in all participants. 
Follow-up time was defined as the time from baseline measurement until cancer diagnosis, death 
from any cause, emigration, or end of study, whichever occurred first. Additionally, the trend 
between specific IgE scores against inhalant allergens and risk of cancer was evaluated by 
assessing scores in groups (0, 1-2, 3-4, 5-6) as an ordinal scale. Levels of IgE are known to 
substantially decrease with age (284). Additionally, the assumption of hazard proportionality was 
not met when serum specific IgE was used as a time varying covariate. Therefore, all analyses 
were performed using age as the time scale.  
 
Models were adjusted for sex, socioeconomic status, and period of measurement, history of 
chronic pulmonary disease to account for asthma and as a proxy for smoking given their 
association to IgE sensitivity and risk of lung cancer (147, 285). Analyses were repeated in men 
and women separately. A further adjustment for categories of total IgE levels was performed in 
the second model. To evaluate any effect modification by total IgE levels, analyses were stratified 
according to total IgE levels. Analysis was subsequently performed for all cancer excluding 
NMSC and the ten most common cancer sites with adjustment for total IgE levels. The analysis 
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was repeated in men and women, but only assessed the five most common cancer sites due to 
the small number of cases.  
 
For the secondary objective, prediagnostic specific IgE was studied in relation to survival after 
cancer diagnosis. Three cancer patients were excluded in the analysis because the diagnosis of 
cancer occurred at time of death, leaving 686 individuals with cancer in the final analysis. Follow-
up time was defined as the time from cancer diagnosis until death from any cause, emigration, or 
end of study, whichever occurred first. Kaplan-Meier curves were used to assess overall survival 
by atopy status and scores of specific IgE, and statistical differences were assessed with the log-
rank test. Cox regression was used to quantify the risks of all-cause and cancer-specific deaths by 
IgE sensitisation status and allergen-specific IgE scores with age at diagnosis as time scale. The 
models were adjusted for the time interval between baseline IgE measurements and cancer 
diagnosis, and total IgE levels.  
 
All analyses were conducted with Statistical Analysis Systems (SAS) release 9.4 (SAS Institute, 





















2.2.3. Serum lactate dehydrogenase and survival following cancer diagnosis  
2.2.3.1. Study population 
In this study (Please see Appendix 1.5 and 1.6 for publication of this study), the association 
between serum LDH and survival was studied in those diagnosed with cancer in AMORIS. A 
total of 7,895 men and women aged 20 and older was selected, with histopathological diagnosis 
of incident cancer between 1986 and 1999 and measurements of prediagnostic serum LDH. 
Follow-up time was defined as time from cancer diagnosis until the date of death from any 
cause, emigration, or end of study (31 December 2011), whichever occurred first. 
 
2.2.3.2. Exposure and outcome assessments 
Serum LDH (ukat/L) was measured automatically (Table 3). Prediagnostic LDH was defined as 
the last measurement taken within 3 years prior to cancer diagnosis. For a secondary analysis, 
LDH levels measured within six-month intervals prior to cancer diagnosis were collected and an 
average was calculated for persons with >1 measurement within any interval time. The 
standardised value (z-score) of LDH was calculated by subtracting with the mean and dividing by 
the standard deviation. Both non-transformed LDH and its z-score were normally distributed. 
Since LDH cut-offs vary across laboratories, its upper limit of normal (ULN) was used to 
categorise LDH into low and high levels ( ULN, > ULN).   
 
Also included in the analysis were socioeconomic status (white collar, blue collar, unemployed or 
unknown) and Charlson co-morbidity index (CCI). CCI consists of 17 groups of diseases with a 
specific weight assigned to each disease category (286), and these weights were then summed to 
obtain an overall score, resulting in four co-morbidity levels (0, 1, 2, and 3+) indicating no co-
morbidity to severe co-morbidity. Period of diagnosis was categorised (before 1989, 1989-1993, 
1993-1997, 1997 onwards) to account for the long period of recruitment and differences in 
cancer management over time. Information on tumour stage was available for 877 breast cancer 
cases (Stage I to IV). 
 
The outcomes of this study were overall death and cancer-specific death. For specific cancer 
sites, cancer-specific deaths were defined as individuals whose primary cause of death matched 




2.2.3.3. Statistical analysis 
Kaplan-Meier curves were used to assess overall survival by categories of prediagnostic LDH, 
and statistical differences were assessed with the log-rank test. Cox proportional hazard 
regression was used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) of 
overall and cause-specific death by z-score and categories of LDH, adjusting for age at diagnosis. 
The proportionality of hazards assumption was met after assessing time-varying covariates which 
were the cross-products of each variable and time. The multivariable model was further adjusted 
for sex, socioeconomic status, CCI, and period of diagnosis. To assess serum LDH at time of 
diagnosis, analyses were repeated in a subgroup of 1,657 participants who had their baseline 
LDH measured within 3 months prior to cancer diagnosis.  
 
To observe the association between baseline LDH and survival in specific cancers, a similar 
multivariable analysis was performed by major cancer sites. For breast cancer, there was 
information available on tumour stage, so that analyses were repeated while adjusting for tumour 
stage. Cumulative incidence functions were used to display cumulative risk of dying from all-
cause and cancer, and statistical difference was assessed with Gray’s test for equality of 
cumulative incidence functions. Kaplan-Meier curves and cumulative incidences were displayed 
only for deaths up to ten years after diagnosis since trends past this cut-off point were similar to 
the ones presented. However, statistical analyses were performed using data for the whole 
follow-up. 
 
In a secondary analysis, the aim was to observe any temporal association between LDH and 
survival in cancer patients. The average of LDH was measured for each six-month time interval 
before cancer diagnosis and associations of LDH with overall and cancer-specific cancer survival 
for each lag time were examined. The models were adjusted for age at diagnosis, sex, 
socioeconomic status, CCI, period of diagnosis, and stratified by cancer sites. A subset analysis 
was performed for breast cancer, stratified by tumour stage (I-II, III-IV).  
 
All analyses were conducted with Statistical Analysis Software (SAS) release 9.4 (SAS Institute, 




2.2.4. Associations of serum glucose and lipids with breast cancer death 
2.2.4.1. Study population 
The objective of this study was to examine the association of serum glucose and lipids with 
breast cancer death in presence of any competing risks (Please see Appendix 1.7 and 1.8 for 
publication of this study). From the AMORIS population, 1,798 women with an incident 
diagnosis of breast cancer between 1985 and 1999 who had baseline measurements of serum 
glucose, triglycerides and total cholesterol within three months to three years prior to diagnosis 
were selected. Follow-up time was defined as the time from diagnosis until death from any 
causes, emigration, or end of study (31 December 2011), whichever occurred first. 
 
2.2.4.2. Exposure and outcome assessments 
Serum levels of glucose (mmol/L), triglycerides (mmol/L), and total cholesterol (mmol/L) were 
measured with standard methods (Table 3). All three markers were measured at the same day, 
within three months to three years prior to diagnosis. This timeframe was selected to capture 
metabolic derangements during ongoing malignancy process while excluding effects of breast 
cancer diagnostic or treatment interventions. Triglycerides levels were not normally distributed, 
and therefore log-transformed values of all markers were used in addition to their quartiles in the 
analysis. Apart from serum markers, information was collected for fasting status (fasting, not 
fasting, unknown) and socioeconomic status (white collar, blue collar, unemployed or unknown). 
 
The main outcome of the study was breast cancer-specific death. In order to evaluate the 
association between the studied markers and this outcome, death from cardiovascular disease 
and other causes was used as competing outcomes.  
 
2.2.4.3. Statistical analysis 
Analyses for this study were performed in two stages. First,  multivariable Cox proportional 
hazards regression was used to assess the association between log-transformed values and 
quartiles of glucose, triglycerides and total cholesterol and the risk of breast cancer death as the 
primary outcome, cardiovascular death and other death as competing outcomes. Adjustment was 
performed for potential confounders including age at diagnosis, socioeconomic status, and 
fasting status at baseline measurements. Glucose, triglycerides and total cholesterol were each 
analysed while adjusting for the other two markers as continuous variables. The proportionality 
of hazards assumption was met after assessing time-varying covariates which were the cross-
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products of each variable and time. To assess any potential competing risk, proportions of 
deaths from breast cancer, cardiovascular disease and other causes were displayed by quartiles of 
glucose, triglycerides, and total cholesterol. 
 
Commonly used methods in survival analysis, including Cox’ proportional hazards, rely on the 
assumption of non-informative censoring. When this assumption is met, any censoring due to 
non-primary events does not affect one’s risk of developing the primary outcome, thus such a 
risk is proportional to the levels of risk factors or covariates observed. However, when 
competing risks are an issue, a heterogeneous association between covariates and the primary 
outcome may exist, reflecting subpopulations or classes with different mortality risk profiles. To 
address this potential heterogeneity, the association between serum glucose, triglycerides and 
total cholesterol and breast cancer survival was subsequently investigated using a latent class 
proportional hazards model. Latent class analysis has been used to identify different classes or 
latent variables within a given population which underlies the pattern of association between 
observed covariates (287). In medical research, the latent class variable has been incorporated 
into various regression analyses, including Cox proportional hazards models, to allow 
identification of subgroups with different risk profile (288–290). To capture heterogeneity in the 
context of breast cancer survival, an extension of the proportional hazards model was used, 
which encompassed latent class variables in addition to glucose, triglycerides and total 
cholesterol, assessed as continuous variables. The number of latent classes present in the cohort 
was identified with Bayesian model selection. To assess breast cancer-specific death whilst 
accounting for competing risks, breast cancer death was incorporated as the primary outcome 
and deaths from cardiovascular disease and other causes as non-primary outcomes into the latent 
class proportional hazards model. Class membership probabilities were retrospectively predicted 
based on associations between covariates and events. Independent samples T-test and Chi2 test 
were used to assess differences in characteristics of study participants and predicted class 
membership. Latent class-specific cumulative mortality functions were further displayed for 
breast cancer, cardiovascular and other death by levels of the three markers. Finally, hazard ratios 
for breast cancer, cardiovascular and other death by levels of glucose, triglycerides, and total 
cholesterol were estimated for each latent class according to the maximum-a-posteriori (MAP) 
likelihood, which took into account all three outcomes (291).  
 
Descriptive analysis and Cox proportional hazards model were performed with Statistical 
Analysis Software (SAS) release 9.3 (SAS Institute, Cary, NC) and R version 3.0.2 (R Project for 
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Statistical Computing, Vienna, Austria). Latent class proportional hazards model were performed 


































Chapter 3: Results 
Relevant findings from studies within this thesis are reported in the following section. Similar to 
the previous chapter, results are presented for each research question separately. 
 
3.1. Systemic Inflammatory Markers in Relation to Breast 
Cancer Risk, Severity, and Survival 
Characteristics of study participants are shown in Table 8. During a mean follow-up of 18.3 
years, 6,606 women were diagnosed with breast cancer, of whom 1,474 died, with breast cancer 
being the main cause of death in 736. Most of the study participants were gainfully employed. 
Higher parity was seen in those who developed breast cancer. Women with breast cancer also 
had higher levels of CRP and haptoglobin at baseline compared to those without. Participants 
with higher levels of CRP, haptoglobin, and WBC and lower albumin were older, less gainfully 
employed, and less likely to be nulliparous (Table 9). 
 
Higher haptoglobin levels were associated with incident breast cancer (Table 10). This 
association slightly weakened in the age- adjusted and fully adjusted model, showing a borderline 
increased risk (HR: 1.09, 95% CI: 1.00-1.18) in the latter. No difference was observed between 
using age as a continuous or categorical variable. When the analysis was stratified based on age of 
50 years as a proxy for menopause in the analysis with truncated follow-up and delayed entry 
(Table 11), a positive association was noted between CRP and breast cancer risk in 
premenopausal women (HR: 1.08, 95% CI: 1.08-1.30), whereas haptoglobin was associated with 
breast cancer risk only in postmenopausal women (HR: 1.09, 95% CI: 1.00-1.19). Similar 
patterns were observed with ordinary stratification analysis, although results were weaker for 
CRP. After adjustment for BMI in the subgroup of women with baseline BMI, the only 
association observed was between haptoglobin and incident breast cancer in postmenopausal 









Table 8. Characteristics of study participants by breast cancer status 





Age (years) – Mean (SD) 50.33 (11.56) 46.26 (14.78) 
Follow-up (years) – Mean (SD) 11.72 (5.48) 18.58 (4.43) 
Parity – No (%)   
Nulliparous 1511 (22.87) 46781 (31.49) 
1+ 5095 (77.13) 101792 (68.51) 
Socioeconomic status – No (%)   
White collar 2930 (44.35) 54935 (36.98) 
Blue collar 3178 (48.11) 74558 (50.18) 
Unemployed or unknown 498 (7.54) 19080 (12.84) 
History of liver disease – No (%) 18 (0.27) 503 (0.34) 
Body mass index (kg/m2)a   
< 18.5 23 (2.05) 733 (3.08) 
18.5-25 739 (65.86) 16002 (67.22) 
25-30 262 (23.35) 5333 (22.40) 
≥ 30 98 (8.73) 1737 (7.30) 
CRP  (mg/L) – No (%)   
< 10 5586 (84.56) 128354 (86.39) 
≥ 10 1020 (15.44) 20219 (13.61) 
Albumin (g/L) – No (%)   
< 40 880 (13.32) 17680 (11.90) 
≥ 40 5726 (86.68) 130893 (88.10) 
Haptoglobin (g/L)b – No (%)   
< 1.4 4118 (86.44) 84221 (87.60) 
≥ 1.4 646 (13.56) 11918 (12.40) 
WBC (109/L)
c 
– No (%)   
< 10 2131 (94.08) 49762 (93.82) 
≥ 10 134 (5.92) 3280 (6.18) 
Measured in a24,297, b100,903 and c55,307 women. 
 
Table 9. Distributions of inflammatory markers and demographical factors 
 CRP (mg/L) Albumin 
(g/L) 
Hp (g/L) WBC(109/L) 
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Table 10.  Hazard ratios and 95% confidence intervals for breast cancer risk by levels of serum 
inflammatory markers in crude and individually adjusted models 
  HR (95% CI) 




CRP  (mg/L)      
< 10 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
≥ 10 1.03 (0.97-1.10) 0.98 (0.91-1.04) 0.99 (0.93-1.06) 1.04 (0.97-1.11) 1.03 (0.96-1.10) 
WBC (109/L)      
< 10 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
≥ 10 0.99 (0.83-1.17) 1.06 (0.89-1.26) 1.03 (0.87-1.23) 1.0 (0.84-1.19) 0.98 (0.82-1.17) 
Albumin (g/L)      
< 40 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
≥ 40 0.88 (0.82-0.94) 0.99 (0.92-1.06) 0.95 (0.89-1.02) 0.87 (0.81-0.93) 0.88 (0.82-0.95) 
Haptoglobin 
(g/L) 
     
< 1.4 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
≥ 1.4 1.19 (1.10-1.30) 1.06 (0.99-1.16) 1.07 (1.00-1.17) 1.21 (1.11-1.31) 1.18 (1.08-1.28) 


























Table 11. Hazard ratios and 95% confidence intervals for breast cancer risk by levels of serum 
inflammatory markers in fully adjusted models 
 N breast 
cancer / 
N total 
HR (95% CI)a,b HR (95% CI)a,c N  breast 
cancer / 
N totalb,d 
HR (95% CI)b,d,e 
All women      
CRP  (mg/L)      
< 10 5586/133940 1.00 (Ref) - 976/21972 1.00 (Ref) 
≥ 10 1020/21239 0.99 (0.92-1.06)  146/2955 0.95 (0.80-1.14) 
WBC (109/L)   -   
< 10 2131/51893 1.00 (Ref) - 179/3881 1.00 (Ref) 
≥ 10 134/3414 1.07 (0.90-1.28) - 12/254 1.10 (0.61-1.99) 
Albumin (g/L)      
< 40 880/18560 1.00 (Ref) - 170/3370 1.00 (Ref) 
≥ 40 5726/136619 0.97 (0.91-1.05) - 952/21557 0.92 (0.79-1.09) 
Haptoglobin 
(g/L) 
     
< 1.4 4118/88339 1.00 (Ref) - 798/17587 1.00 (Ref) 
≥ 1.4 646/12564 1.09 (1.00-1.18) - 124/2233 1.20 (0.99-1.45) 
Premenopause      
CRP  (mg/L)      
< 10 2882/84511 1.00 (Ref) 1.00 (Ref) 559/14588 1.00 (Ref) 
≥ 10 497/11663 1.18 (1.08-1.30) 1.02 (0.93-1.13) 79/1774 1.14 (0.90-1.44) 
WBC (109/L)      
< 10 891/28729 1.00 (Ref) 1.00 (Ref) 95/2391 1.00 (Ref) 
≥ 10 71/2073 1.04 (0.81-1.32) 1.07 (0.84-1.36) 6/164 0.84 (0.37-1.92) 
Albumin (g/L)      
< 40 370/9241 1.00 (Ref) 1.00 (Ref) 91/2058 1.00 (Ref) 
≥ 40 3009/86933 0.92 (0.83-1.02) 1.01 (0.90-1.12) 547/14304 0.87 (0.70-1.09) 
Haptoglobin 
(g/L) 
     
< 1.4 2266/55976 1.00 (Ref) 1.00 (Ref) 482/11832 1.00 (Ref) 
≥ 1.4 248/5956 0.94 (0.83-1.07) 0.93 (0.82-1.06) 56/1225 1.04 (0.79-1.38) 
Postmenopaused      
CRP  (mg/L)      
< 10 4730/109139 1.00 (Ref) 1.00 (Ref) 817/18767 1.00 (Ref) 
≥ 10 893/18560 1.00 (0.93-1.07) 0.97 (0.88-1.07) 129/2633 0.99 (0.82-1.20) 
WBC (109/L)      
< 10 1845/42027 1.00 (Ref) 1.00 (Ref) 155/3304 1.00 (Ref) 
≥ 10 115/2810 1.06 (0.88-1.28) 1.02 (0.79-1.31) 9/231 0.95 (0.48-1.86) 
Albumin (g/L)      
< 40 792/16325 1.00 (Ref) 1.00 (Ref) 145/2953 1.00 (Ref) 
≥ 40 4831/111374 0.95 (0.88-1.03) 0.92 (0.84-1.02) 801/18447 0.93 (0.78-1.12) 
Haptoglobin 
(g/L) 
     
< 1.4 3524/75302 1.00 (Ref) 1.00 (Ref) 666/15190 1.00 (Ref) 
≥ 1.4 589/11617 1.09 (1.00-1.19) 1.19 (1.07-1.33) 114/2084 1.24 (1.01-1.51) 
aAdjusted for age at baseline measurement (continuous), socioeconomic status, and parity  
bAge of 50 years was used as a proxy for menopause. In the analysis of pre-menopausal women, individuals were followed to age 
50 after which they were censored. In the assessment of post-menopausal risk, individuals with a baseline measurement taken 
before age 50 entered the study at age 50 by means of delayed entry. Note that this analysis allowed the same participants to be 
included in both groups, which resulted in a difference between the total numbers from pre-and post-menopausal analyses with 
the actual total numbers of women in the cohort. 
cStratification analysis by age of 50 years without truncated follow-up or delayed entry 
dSubcohort analysis in women with baseline BMI 






Figure 16 shows the proportions of breast cancer severity with respect to categories of 
prediagnostic CRP, albumin, haptoglobin and WBC, where no marked difference was observed 
between women with high and low levels of these markers. No association was found between 
these markers and the odds of being diagnosed with more severe breast cancer (Table 12).  
 
High prediagnostic haptoglobin was linked to increased risk of dying from breast cancer (HR: 
1.27, 95% CI: 1.02-1.59). A similar association was seen with CRP, but disappeared after 
adjustment for other covariates. For all-cause mortality, a stronger association with prediagnostic 
markers was found (Table 13). Women with higher levels of CRP, haptoglobin, and WBC are at 
greater risk of early death from any causes, with HR of 1.19 (95% CI: 1.04-1.36), 1.34 (1.15-1.55) 
and 1.57 (1.14-2.16) for high versus low levels of CRP, haptoglobin, and WBC, respectively. An 
inverse association for albumin was not apparent after adjustment for other covariates.  
 
The association between prediagnostic serum inflammatory markers and death following breast 
cancer diagnosis was further demonstrated with cumulative incidence functions. A statistically 
significant higher cumulative risk of dying from breast cancer was observed in women with 
higher prediagnostic CRP and haptoglobin compared to those with lower levels (Figure 17). 
Similar but stronger trends were seen with all-cause death. Additionally, an inverse trend was 
observed between albumin and all-cause mortality over time. Although the hazard 
proportionality test showed no violation of the proportional hazard (P>0.05), cumulative 
incidence functions for WBC categories showed that hazard proportionality requirement was not 
met in longer follow-up. On the other hand, BCa survival by CRP categories was more evident 















Figure 16. Proportion of breast cancer severity categories by levels of prediagnostic inflammatory 
markers  
 
Table 12. Proportional odds ratios and 95% confidence intervals of more severe breast cancer by levels 
of prediagnostic serum inflammatory markers 
 Proportional OR (95% CI)  
Crude Adjusteda 
CRP  (mg/L)   
< 10 1.00 (Ref) 1.00 (Ref) 
≥ 10 1.04 (0.89-1.21) 1.04 (0.88-1.23) 
WBC (109/L)   
< 10 1.00 (Ref) 1.00 (Ref) 
≥ 10 1.03 (0.70-1.52) 1.08 (0.73-1.60) 
Albumin (g/L)   
< 40 1.00 (Ref) 1.00 (Ref) 




< 1.4 1.00 (Ref) 1.00 (Ref) 
≥ 1.4 1.13 (0.93-1.37) 1.14 (0.94-1.39) 
aAdjusted for age (continuous) and menopausal status at diagnosis, period of diagnosis, interval time between measurement and 





Table 13. Hazard ratios and 95% confidence intervals for deaths in breast cancer patients by levels of 
prediagnostic serum inflammatory markers 
 N  death / N breast 
cancer 
HR (95% CI) 
Crude Adjusteda 
Breast cancer-specific death   
CRP  (mg/L)    
< 10 597 / 5584 1.00 (Ref) 1.00 (Ref) 
≥ 10 139 / 1022 1.22 (1.01-1.46) 1.16 (0.95-1.41) 
Albumin (g/L)    
< 40 113 / 878 1.00 (Ref) 1.00 (Ref) 
≥ 40 623 / 5728 0.88 (0.72-1.08) 0.92 (0.75-1.13) 
Haptoglobin (g/L)    
< 1.4 417 / 4107 1.00 (Ref) 1.00 (Ref) 
≥ 1.4 95 / 655 1.31 (1.05-1.64) 1.27 (1.02-1.59) 
WBC (109/L)    
< 10 240 / 2132 1.00 (Ref) 1.00 (Ref) 
≥ 10 17 / 1332 1.23 (0.75-2.01) 1.23 (0.75-2.03) 
All-cause death    
CRP  (mg/L)    
< 10 1162 / 5584 1.00 (Ref) 1.00 (Ref) 
≥ 10 312 / 1022 1.38 (1.21-1.56) 1.19 (1.04-1.36) 
Albumin (g/L)    
< 40 256 / 878 1.00 (Ref) 1.00 (Ref) 
≥ 40 1218 / 5728 0.78 (0.68-0.89) 0.95 (0.83-1.09) 
Haptoglobin (g/L)    
< 1.4 914 / 4107 1.00 (Ref) 1.00 (Ref) 
≥ 1.4 219 / 655 1.55 (1.34-1.80) 1.34 (1.15-1.55) 
WBC (109/L)    
< 10 573 / 2132 1.00 (Ref) 1.00 (Ref) 
≥ 10 42 / 132 1.25 (0.92-1.71) 1.57 (1.14-2.16) 
aAdjusted for age (continuous) and menopausal status at diagnosis, TNM stage, ER status, period of diagnosis, interval time 

















Figure 17. Cumulative mortality risk in breast cancer patients by levels of prediagnostic serum inflammatory markers. Note the different axes used in breast cancer-
specific and all-cause death. 
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3.2. Atopy and Cancer 
Characteristics of study participants by atopy status are shown in Table 14. The average age at 
baseline was 40 years, and more than half of the study population were female (59%). During a 
mean follow-up of 16 years, 689 persons were diagnosed with incident cancer. The most 
common three types of cancer were prostate, female breast, and colorectal cancers.  
 
As shown in Figure 18, most individuals without atopy (specific IgE score of 0) had low or 
moderate levels of serum total IgE. The proportion of study participants with high total IgE 
increased with higher specific IgE scores, and nearly equalled total participants with specific IgE 
score of 5 and 6.  
 
No association between atopy and risk of cancer was found (Table 15), but a statistically 
significant inverse trend was observed between highest serum specific IgE scores and risk of 
cancer in the overall study population and in women separately. Adjustment for serum total IgE 
showed stronger associations and an inverse association between atopy and cancer risk in the 
overall population. However, no marked difference in cancer risk by atopy status was noted in 
men and women separately. When analyses were stratified by serum total IgE levels, the inverse 
trend was only seen between serum specific IgE scores and cancer risk in the overall population 
and in women, but not men. No statistical significant interaction was found between serum total 
IgE categories and atopy or specific IgE scores (Pinteraction >0.05). 
 
Using the models above with an additional adjustment for serum total IgE, the risk of the most 
common cancers was evaluated. Overall, no marked association was found between atopy and 
risk of specific cancers assessed (Table 16). When trends across specific IgE scores were 
observed, there was a lower risk of melanoma with higher specific IgE in both men and women 
combined (Ptrend = 0.04). No clear association was observed for other cancer sites. In sex 
stratification, an inverse trend, albeit weak, was shown between specific IgE scores and 







Table 14. Characteristics of study participants by atopy status 
 No atopy (N = 4,714) Atopy (N = 4,013) 
Age (years) – Mean (SD) 42.26 (13.74) 37.31 (12.66) 
Sex, male – No (%) 1661 (35.24) 1945 (48.47) 
Socioeconomic status – No (%)   
White collar 1912 (40.56) 1423 (35.46) 
Blue collar 2074 (44.00) 1697 (42.49) 
Unemployed/unknown 728 (15.44) 893 (22.25) 
History of chronic respiratory disease – No (%) 67 (1.42) 92 (2.29) 
Year of measurement – No (%)   
1992-1993 1192 (25.29) 986 (24.57) 
1994-1996 2682 (56.89) 1997 (49.76) 
1996 840 (17.82) 1030 (25.67) 
Total IgE (kU/L) – No (%)   
< 25 1765 (37.44) 285 (7.10) 
25-100 1937 (41.09) 1355 (33.77) 
≥ 100 1012 (21.47) 2373 (59.13) 
Mean follow-up (years) – Mean (SD) 15.86 (3.59) 16.05 (3.23) 
Any cancer during follow-up – No (%)    
All cancer 443 (9.40) 246 (6.13) 
Prostate 115 (2.44) 50 (1.25) 
Breast (female) 55 (1.17) 42 (1.05) 
Colorectal 43 (0.91) 21 (0.52) 
Gynaecological 41 (0.87) 12 (0.30) 
Haematological 31 (0.66) 22 (0.55) 
Melanoma 27 (0.57) 10 (0.25) 
Pulmonary 21 (0.45) 14 (0.35) 
Bladder 14 (0.30) 11 (0.27) 
CNS 11 (0.23) 9 (0.22) 
Kidney 12 (0.25) 9 (0.22) 
























































HR (95% CI) 
Atopy Specific IgE scoresa 
No atopy Atopy 0 1-2 3-4 5-6 Ptrend 
Both men and women         
Multivariable model 689/8727 1.0 (Ref) 0.87 (0.74-1.02) 1.0 (Ref) 0.99 (0.82-1.20) 0.73 (0.58-0.91) 0.88 (0.53-1.46) 0.02 
Additional adjustment for total IgE 689/8727 1.0 (Ref) 0.82 (0.76-0.99) 1.0 (Ref) 0.95 (0.77-1.16) 0.68 (0.53-0.87) 0.76 (0.45-1.29) 0.003 
Stratification by total IgE (kU/L)          
< 25  191/2050 1.0 (Ref) 0.79 (0.48-1.31) 1.0 (Ref) 0.86 (0.51-1.47) 0.48 (0.12-1.96) N/A 0.28 
25-100 238/3292 1.0 (Ref) 0.84 (0.63-1.11) 1.0 (Ref) 0.91 (0.65-1.27) 0.75 (0.50-1.13) N/A 0.14 
> 100 260/3385 1.0 (Ref) 0.81 (0.63-1.04) 1.0 (Ref) 0.99 (0.74-1.33) 0.65 (0.47-0.89) 0.79 (0.46-1.35) 0.02 
Men          
Multivariable model 277/3606 1.0 (Ref) 0.94 (0.74-1.20) 1.0 (Ref) 0.99 (0.74-1.34) 0.86 (0.63-1.18) 1.18 (0.59-2.35) 0.60 
Additional adjustment for total IgE 277/3606 1.0 (Ref) 0.87 (0.67-1.13) 1.0 (Ref) 0.93 (0.68-1.27) 0.79 (0.57-1.11) 1.01 (0.49-2.06) 0.27 
Stratification by total IgE (kU/L)          
< 25  53/649 1.0 (Ref) 0.70 (0.29-1.72) 1.0 (Ref) 0.59 (1.20-1.74) 1.08 (0.26-4.56) N/A 0.61 
25-100 97/1377 1.0 (Ref) 0.81 (0.53-1.25) 1.0 (Ref) 0.97 (0.58-1.64) 0.66 (0.36-1.19) N/A 0.20 
> 100 127/1580 1.0 (Ref) 0.94 (0.64-1.37) 1.0 (Ref) 0.99 (0.63-1.54) 0.86 (0.55-1.35) 1.14 (0.54-2.42) 0.79 
Women          
Multivariable model 412/5121 1.0 (Ref) 0.82 (0.67-1.02) 1.0 (Ref) 0.98 (0.76-1.26) 0.63 (0.45-0.89) 0.71 (0.33-1.51) 0.01 
Additional adjustment for total IgE 412/5121 1.0 (Ref) 0.80 (0.63-1.01) 1.0 (Ref) 0.96 (0.73-1.24) 0.60 (0.42-0.86) 0.63 (0.29-1.37) 0.009 
Stratification by total IgE (kU/L)          
< 25  138/1401 1.0 (Ref) 0.82 (0.44-1.53) 1.0 (Ref) 0.98 (0.53-1.83) N/A N/A 0.30 
25-100 141/1915 1.0 (Ref) 0.86 (0.59-1.25) 1.0 (Ref) 0.85 (0.54-1.34) 0.89 (0.51-1.55) N/A 0.47 
> 100 133/1805 1.0 (Ref) 0.73 (0.51-1.03) 1.0 (Ref) 0.98 (0.66-1.46) 0.51 (0.31-0.83) 0.62 (0.28-1.38) 0.01 
aHighest specific IgE scores recorded at baseline 
N/A = not applicable 








HR (95% CI) 
Atopy Specific IgE scoresa 
No atopy Atopy 0 1-2 3-4 5-6 Ptrend 
Both men and women         
All excluding NMSCb 664 1.0 (Ref) 0.82 (0.69-0.99) 1.0 (Ref) 0.96 (0.78-1.18) 0.67 (0.52-0.85) 0.81 (0.48-1.36) 0.005 
Colorectal 64 1.0 (Ref) 0.70 (0.39-1.26) 1.0 (Ref) 0.75 (0.38-1.51) 0.59 (0.26-1.34) 1.22 (0.27-5.34) 0.31 
Haematological 53 1.0 (Ref) 0.94 (0.51-1.75) 1.0 (Ref) 1.15 (0.58-2.29) 0.65 (0.27-1.58) 1.19 (0.27-5.38) 0.60 
Melanoma 37 1.0 (Ref) 0.51 (0.23-1.15) 1.0 (Ref) 0.78 (0.33-1.86) 0.32 (0.09-1.10) N/A 0.04 
Pulmonary 35 1.0 (Ref) 0.87 (0.41-1.84) 1.0 (Ref) 1.24 (0.56-2.76) 0.40 (0.11-1.43) 0.94 (0.12-7.41) 0.22 
Bladder 25 1.0 (Ref) 1.17 (0.49-2.81) 1.0 (Ref) 1.43 (0.55-3.73) 0.92 (0.28-3.04) N/A 0.80 
Kidney 21 1.0 (Ref) 1.08 (0.40-2.91) 1.0 (Ref) 1.49 (0.52-4.27) 0.26 (0.03-2.18) 3.28 (0.60-17.82) 0.98 
CNS 20 1.0 (Ref) 1.30 (0.47-3.69) 1.0 (Ref) 1.81 (0.62-5.29) 0.86 (0.21-3.53) N/A 0.71 
Men         
All excluding NMSCb 267 1.0 (Ref) 0.89 (0.68-1.16) 1.0 (Ref) 0.95 (0.69-1.31) 0.80 (0.57-1.13) 1.12 (0.55-2.28) 0.37 
Prostate 97 1.0 (Ref) 0.90 (0.58-1.40) 1.0 (Ref) 0.84 (0.49-1.45) 0.90 (0.51-1.56) 2.12 (0.72-6.27) 0.93 
Colorectal 35 1.0 (Ref) 0.68 (0.32-1.44) 1.0 (Ref) 0.76 (0.31-1.86) 0.51 (0.18-1.44) 1.66 (0.34-7.99) 0.44 
Haematological 23 1.0 (Ref) 1.12 (0.44-2.87) 1.0 (Ref) 1.10 (0.36-3.35) 1.11 (0.34-3.61) 1.33 (0.15-11.99) 0.79 
Pulmonary 15 1.0 (Ref) 1.07 (0.35-3.26) 1.0 (Ref) 1.41 (0.42-4.71) 0.57 (0.11-3.02) 2.38 (0.24-23.99) 0.93 
Melanoma 12 1.0 (Ref) 0.54 (0.15-2.00) 1.0 (Ref) 0.63 (0.13-3.12) 5.12 (0.10-2.68) N/A 0.31 
Women         
All excluding NMSCb 397 1.0 (Ref) 0.81 (0.63-1.03) 1.0 (Ref) 0.98 (0.75-1.28) 0.57 (0.39-0.83) 0.65 (0.30-1.42) 0.008 
Breast 165 1.0 (Ref) 0.83 (0.57-1.20) 1.0 (Ref) 0.95 (0.62-1.44) 0.69 (0.40-1.19) 0.49 (0.12-2.03) 0.14 
Gynaecological 53 1.0 (Ref) 0.55 (0.27-1.13) 1.0 (Ref) 0.54 (0.22-1.32) 0.65 (0.25-1.64) N/A 0.11 
Colorectal 29 1.0 (Ref) 0.76 (0.30-1.95) 1.0 (Ref) 0.75 (0.25-2.28) 0.87 (0.23-3.19) N/A 0.56 
Haematological 30 1.0 (Ref) 0.83 (0.37-1.87) 1.0 (Ref) 1.13 (0.48-2.70) 0.37 (0.08-1.63) 1.09 (0.14-8.74) 0.40 
Melanoma 25 1.0 (Ref) 5.02 (0.18-1.38) 1.0 (Ref) 0.85 (0.30-2.39) 0.18 (0.02-1.45) N/A 0.06 
aHighest specific IgE scores recorded at baseline 
N/A = not applicable; NMSC = nonmelanoma skin cancer; CNS = central nervous system 
All models used age as a timescale and were adjusted for sex (except for sex-specific analysis), socioeconomic status, period of measurement, history of chronic pulmonary disease, and serum total IgE  
bNMSC was excluded in this analysis due to underreporting in population cancer registries (283)
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In our secondary analysis, we assessed risk of death following cancer diagnosis. As shown by the 
Kaplan-Meier curves in, the probability of survival was lower in men with IgE sensitisation 
compared to those without in the long term follow-up but there were no statistically significant 
difference (Log-rank P >0.05). Similarly, no differences were observed when categories of 
allergen-specific IgE scores were used (results not shown). We further evaluated this association 
by conducting Cox regression and found no clear associations between IgE sensitisation or 
specific IgE scores and death from all-causes or cancer, e.g. HR for cancer death was 1.04 (95% 
CI: 0.59-1.84) and 1.54 (0.91-2.62) for men and women with compared to without IgE 
sensitisation, respectively (results not shown in tables). 
 
 
Figure 19. Kaplan-Meier curves of 10-year survival following cancer diagnosis in (a) men and (b) 
women based on prediagnostic IgE sensitisation. Thick lines indicate IgE sensitisation and the 










3.3. Serum Lactate Dehydrogenase and Survival Following 
Cancer Diagnosis 
Characteristics of study participants by LDH categories are shown in Table 17. Mean age at 
diagnosis was 62 years. At the end of follow up (mean: 8.2 years), 5,799 participants (73.5%) 
were deceased. Participants with high levels of baseline LDH (>ULN) were older, had higher co-
morbidity burden, and lower 5-year overall survival rates. The three most frequent cancers were 
breast (female), prostate and colorectal cancer. 
 
Overall survival differed by LDH measured within 3 years prior to diagnosis and within 3 
months before date of diagnosis, i.e. LDH at time at diagnosis, with lower survival seen with 
higher LDH (Figure 20). Correspondingly, multivariable Cox proportional hazards regression 
showed an increased risk of dying from all causes with higher LDH z-score or categories, with a 
hazard ratio (HR) of 1.78 (95% CI: 1.64–1.94) comparing LDH levels above and below ULN. 
Similar findings were found when assessing cancer-specific death, e.g. the HR for overall cancer 
death was 1.85 (95% CI: 1.68–2.03) for high versus low LDH. Associations were slightly 
attenuated when the models were adjusted by cancer site Similar but more evident associations 
were found in the sub-analysis only including serum LDH at time at diagnosis (Table 18).  
 
When specific cancer sites were assessed, higher risk of overall death was observed with high 
LDH in individuals diagnosed with breast, prostate, pulmonary, colorectal, gastroesophagealand 
haematological cancer and melanoma (Figure 21). The strongest association was seen for 
prostate cancer (HR: 2.19, 95% CI: 1.63–2.95). Similar but weaker trends were found when 
assessing cancer-specific death, with a positive association between LDH and risk of dying from 
prostate, pulmonary, colorectal, gastroesophageal, and haematological cancer. Additionally, a 
positive association was seen with gynaecological cancer death. In a subgroup analysis of 877 
women with breast cancer and available information on tumour stage, adjustment for tumour 
stage did not alter the associations between LDH and death, with HR of all-cause and breast 
cancer death of 1.73 (95% CI: 1.12–2.67) and 1.54 (95%CI: 0.81–2.92), respectively, for high 






Table 17. Characteristics of participants by categories of serum LDH measured within 3 years prior to 
cancer diagnosis 
 LDH 
  ULN (N = 7,216) > ULN (N = 679) 
Age at diagnosis (years) – Mean (SD) 62.29 (12.71) 65.62 (12.89) 
Sex, male – No (%) 3682 (51.03) 381 (56.11) 
Socioeconomic status – No (%)   
White collar 3136 (43.46) 237 (34.90) 
Blue collar 2774 (38.44) 247 (36.38) 
Unemployed or unknown 1306 (18.20) 195 (28.72) 
Charlson comorbidity index – No (%)   
0 5871 (81.36) 525 (77.32) 
1 871 (12.07) 82 (12.08) 
2 252 (3.49) 37 (5.45) 
3+ 222 (3.08) 35 (5.15) 
Period of diagnosis – No (%)   
Before 1989 1480 (20.51) 166 (24.45) 
1989-1993 2215 (30.70) 235 (34.61) 
1993-1997 2399 (33.25) 229 (33.72)  
1997 onwards 1122 (15.56) 49 (7.22) 
Cancer site – No (%)   
Breast 1081 (14.98) 37 (5.45) 
Prostate 832 (11.53) 49 (7.22) 
Pulmonary 598 (8.29) 70 (10.31) 
Colorectal 784 (10.86) 82 (12.08) 
Gastroesophageal 296 (4.10) 22 (3.24) 
Hepatobiliary 130 (1.80) 36 (5.30) 
Pancreas 222 (3.08) 35 (5.15) 
Kidney  199 (2.76) 25 (3.68) 
Bladder 335 (4.64) 14 (2.06) 
Gynaecological 486 (6.74) 42 (6.19) 
Head and neck 134 (1.86) 11 (1.62) 
Melanoma 259 (3.59) 13 (1.91) 
Central nervous system 302 (4.19) 14 (2.06) 
Haematological 567 (7.86) 122 (17.97) 
Survival time (months) - Median 67.81 13.72 






Figure 20. Kaplan-Meier curves for ten-year overall survival following cancer diagnosis by serum LDH 
levels measured (a) within 3 years prior to diagnosis, and (b) within 3 months prior to diagnosis 
 
Table 18. Hazard ratios and 95% confidence intervals for death following cancer diagnosis by 
prediagnostic levels of LDH 
 LDH 
z-score  ULN > ULN 
All-cause death    
N death/N total  5187 / 7216 612 / 679 
Age-adjusted 1.18 (1.16-1.21) 1.0 (Ref) 1.78 (1.64-1.94) 
Multivariablea  1.16 (1.14-1.19) 1.0 (Ref) 1.66 (1.53-1.81) 
Adjusted by cancer sitea 1.12 (1.10-1.15) 1.0 (Ref) 1.43 (1.31-1.56) 
Sampling  3 months before diagnosisb 1.15 (1.12-1.18) 1.0 (Ref) 1.91 (1.65-2.20) 
Cancer-specific death    
N death/N total  3760 / 7216 462 / 679 
Age-adjusted 1.19 (1.17-1.22) 1.0 (Ref) 1.85 (1.68-2.03) 
Multivariablea 1.17 (1.14-1.20) 1.0 (Ref) 1.72 (1.56-1.90) 
Adjusted by cancer sitea 1.12 (1.10-1.15) 1.0 (Ref) 1.46 (1.32-1.61) 
Sampling  3 months before diagnosisb 1.17 (1.12-1.20) 1.0 (Ref) 2.06 (1.76-2.41) 
aAdjusted for age at diagnosis (continuous), sex, socioeconomic status, Charlson comorbidity index, and period of diagnosis 
bSubanalysis in 1,657 participants. Adjusted for age at diagnosis (continuous), sex, socioeconomic status, Charlson comorbidity 






Figure 21. Hazard ratios and 95% confidence intervals for death following cancer diagnosis for high (> ULN) compared to low serum LDH ( ULN) as the 




The association between LDH and cancer was further visualised with cumulative incidence 
functions (Figure 22) and found higher cumulative risks of dying from overall, prostate, 
pulmonary, colorectal, gastroesophageal, kidney, gynaecological, and haematological cancer with 
high LDH levels. Interestingly, an inverse association was observed for head and neck cancer 
which approached statistical significance (Gray’s test P = 0.05).  
 
In the secondary analysis, LDH measured within six-month time intervals before cancer 
diagnosis was found to be increasing in interval times closer to diagnosis for overall and several 
types of cancer such as hepatobiliary and haematological cancer (Figure 23).  
 
When risk of overall death in all participants was assessed for every interval time, a stronger 
association was observed with mean LDH measured closer to diagnosis, i.e. within 1 year prior 
to diagnosis. However, an increased risk of early death was found in those with high LDH 
measured 30 to 36 months prior to diagnosis (HR: 1.46, 95% CI: 1.15–1.86). For cancer-specific 
death, associations were also stronger when LDH was measured closer to diagnosis (Table 19). 
Similarly, in patients with stage I to II breast cancer, a positive association was observed between 
LDH measured 30 to 36 months before diagnosis and overall death (HR: 2.97, 95% CI: 1.38–
6.39), and between LDH measured 6 to 12 months before diagnosis and breast cancer death 
(HR: 1.95, 95% CI: 1.24–16.00). Results in advanced stage of disease were hampered by a low 















Figure 23. The average of serum LDH measured within 6-month interval times prior to cancer diagnosis, stratified by cancer site
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Table 19. Hazard ratios and 95% confidence intervals for temporal associations between serum LDH 






z-score  ULN > ULN 
All–cause death    
0–6 1952 / 2426 1.14 (1.11-1.17) 1.0 (Ref) 2.01 (1.79-2.25) 
6–12 1124 / 1523 1.10 (1.03-1.18) 1.0 (Ref) 1.48 (1.21-1.83) 
12–18 1188 / 1620 1.04 (0.96-1.12) 1.0 (Ref) 1.01 (0.79-1.31) 
18–24 1176 / 1589 1.10 (1.02-1.18) 1.0 (Ref) 1.23 (0.96-1.57) 
24–30 1287 / 1750 1.04 (0.96-1.13) 1.0 (Ref) 1.16 (0.90-1.51) 
30–36 1300 / 1818 1.10 (1.01-1.19) 1.0 (Ref) 1.46 (1.15-1.86) 
Cancer–specific death    
0–6 1498 / 2426 1.15 (1.12-1.18) 1.0 (Ref) 2.11 (1.86-2.40) 
6–12 801 / 1523 1.11 (1.02-1.20) 1.0 (Ref) 1.54 (1.21-1.96) 
12–18 839 / 1620 1.04 (0.95-1.15) 1.0 (Ref) 1.08 (0.80-1.47) 
18–24 837 / 1589 1.07 (0.98-1.17) 1.0 (Ref) 1.07 (0.79-1.46) 
24–30 913 / 1750 0.99 (0.90-1.10) 1.0 (Ref) 0.97 (0.68-1.38) 
30–36 906 / 1818 1.04 (0.94-1.15) 1.0 (Ref) 1.10 (0.80-1.52) 
aInterval time between baseline measurement of serum LDH and cancer diagnosis 
bAverage of serum LDH measurements taken within each interval time  
All models were adjusted for age at diagnosis (continuous), sex, socioeconomic status, Charlson comorbidity index, period of 
diagnosis, and stratified by cancer sites
3.4. Associations of Serum Glucose and Lipids with Breast 
Cancer Death  
At the end of follow up (mean: 13 years), a total of 861 (47.9%) study participants were 
deceased. Among these women, 425 died from breast cancer, 179 from cardiovascular disease, 
and 257 from other causes. The mean age of all participants was 58 at breast cancer diagnosis. 
Levels of glucose, triglycerides, and total cholesterol were highest in those dying from 
cardiovascular disease, whereas women who died from breast cancer had lower levels of the 
three markers compared to all women dying during follow-up period (Table 20). 
 
When conventional Cox proportional hazards regression was performed, no strong association 
was observed between glucose, triglycerides, and total cholesterol and risk of dying from breast 
cancer (Table 21). On the other hand, positive associations were observed between triglycerides 
and cardiovascular death, as well as glucose and cardiovascular death. No association was 
observed for other causes of death. Proportions of deaths from each cause by quartiles of 
glucose, triglycerides, total cholesterol were displayed using the cumulative incidence functions. 
As shown in Figure 24, the proportion of women dying from cardiovascular disease markedly 
increased with higher quartiles of the markers, whilst deaths from breast cancer are less frequent 
with higher quartiles of the markers. This indicated cardiovascular death as a competing event. 
 
The next analysis extended the proportional hazards model to include latent class variables and 
assess primary and non-primary outcomes. Bayesian model selection identified two latent classes 
in this study population. Retrospective analysis for class membership probability suggested that 
81.5% women were more likely to be members of Class I, while the other 18.5% belonged to 
Class II. Baseline characteristics of study participants were further assessed in relation to the 
most probable latent class they were assigned to. Younger average age was observed in Class I 
compared to Class II, and a difference in socioeconomic status between classes was indicated 
(Table 22). With regards to clinical outcomes, no difference in proportions of women who died 
from breast cancer was found between the two classes. However, statistically significantly higher 
overall mortality rate from cardiovascular disease and other causes were seen in Class II.  
 
 
Table 20. Characteristics of study participants overall and by causes of death 
 All 
participants 
(n = 1,798) 
Overall 
death 










Age (years) – Mean (SD) 58.10 (11.82) 62.4 (13.22) 56.52 (12.47) 71.00 (10.25) 66.22 (11.38) 
Follow-up time (years) – Mean (SD) 13.34 (6.90) 8.26 (5.91) 6.40 (5.04) 9.28 (6.47) 10.61 (5.96) 
Interval between measurements and diagnosis (months) – Mean (SD) 18.26 (9.24) 18.10 (9.24) 18.36 (9.00) 17.64 (9.48) 17.88 (9.24) 
Socioeconomic status      
White collar 648 (36.04 235 (27.29) 147 (34.59) 30 (16.76) 58 (22.57) 
Blue collar 894 (49.72 405 (47.04) 222 (52.24) 61 (34.08) 122 (47.47) 
Unemployed or unknown 256 (14.24) 221 (25.67) 56 (14.18) 88 (49.16) 77 (29.96) 
Fasting status      
Fasting 1027 (57.12) 508 (59.00) 242 (56.94) 107 (59.78) 
 
159 (61.87) 
Not fasting 568 (31.59) 254 (29.50) 133 (31.30) 52 (29.05) 69 (26.85) 
Unknown 203 (11.29) 99 (11.50) 50 (11.76) 20 (11.17) 29 (11.28) 
Glucose (mmol/L) – Mean (SD) 5.10 (1.24) 5.25 (1.36) 5.04 (1.02) 5.46 (1.18) 5.44 (1.84) 
Triglycerides (mmol/L) – Mean (SD) 1.27 (0.82) 1.40 (0.90) 1.30 (0.91) 1.62 (0.95) 1.42 (0.82) 
Total cholesterol (mmol/L) – Mean (SD) 5.94 (1.17) 6.11 (1.24) 5.89 (0.53) 6.51 (1.21) 6.20 (1.19) 
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Breast cancer death Cardiovascular death Other death 
N event HRa 95% CI N event HRa 95% CI N 
event 
HRa 95% CI 
Glucose, mmol/Lb          
Continuous log   0.96  (0.58-1.59)  2.48 (1.24-4.96)  2.09 (1.16-3.76) 
Quartiles           
<4.50 393 98 1 (Ref) 21 1 (Ref) 45 1 (Ref) 
4.50-4.90 413 116 0.98  (0.75-1.29) 36 1.27 (0.74-2.19) 63 1.12 (0.76-1.64) 
4.90-5.30 363 96 0.95  (0.72-1.27) 41 1.28 (0.75-2.19) 50 0.87 (0.58-1.30) 
≥5.30 416 115 0.98  (0.74-1.29) 80 1.67 (1.02-2.73) 100 1.32 (0.92-1.89) 
Ptrend   0.83   0.03   0.20  
Triglycerides, mmol/Lc          
Continuous log   1.21  (0.98-1.48)  1.58 (1.17-2.13)  1.32 (1.02-1.71) 
Quartiles           
<0.70 297 81 1 (Ref) 12 1 (Ref) 24 1 (Ref) 
0.70-1.00 491 102 0.77  (0.57-1.04) 34 0.91 (0.46-1.77) 56 0.96 (0.59-1.57) 
1.00-1.60 555 132 0.97  (0.72-1.29) 52 1.10 (0.58-2.08) 95 1.28 (0.81-2.03) 
≥1.60 455 110 1.05  (0.76-1.45) 80 1.53 (0.81-2.90) 83 1.22 (0.75-1.98) 
Ptrend   0.35   0.01   0.16  
Total cholesterol, mmol/Ld          
Continuous log   0.72  (0.40-1.28)  2.04 (0.83-5.04)  0.67 (0.32-1.42) 
Quartiles           
<5.20 443 119 1 (Ref) 16 1 (Ref) 38 1 (Ref) 
5.20-5.80 403 94 0.87  (0.66-1.14) 37 1.52 (0.83-2.76) 60 1.18 (0.78-1.79) 
5.80-6.60 470 102 0.79  (0.60-1.04) 40 1.26 (0.70-2.27) 75 1.06 (0.72-1.58) 
≥6.60 482 110 0.85 (0.64-1.15) 85 1.74 (0.99-3.04) 85 0.92 (0.61-1.38) 
Ptrend   0.21   0.08   0.38  
aAdjusted for age at diagnosis (continuous), socioeconomic status, fasting status, glucose (continuous), triglycerides (continuous), and total cholesterol (continuous) 




Figure 24. Stacked cumulative risk of death from breast cancer (BC), cardiovascular disease (CV), and other causes, stratified by quartiles of glucose, triglycerides 
(TG) and total cholesterol (TC). 
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Table 22. Characteristics of study participants and causes of death by predicted class membership 
 Breast cancer patients  
P-value  Class I 
(N = 1,466) 
Class II 
(N = 332) 
Age (years) – Mean (SD) 57.56 (10.91) 60.51 (14.99) <0.0001 
Socioeconomic status, No (%)   <0.0001 
White collar 554 (37.79) 94 (28.31)  
Blue collar 739 (50.41) 155 (46.69)  
Unemployed or missing 173 (11.80) 83 (25.00)  
Fasting status, No (%)   0.55 
Fasting 827 (56.41) 200 (60.24)  
Not fasting 477 (32.54) 91 (27.41)  
Missing 162 (11.05) 41 (12.35)  
Glucose  (mmol/L) – Mean (SD) 5.12 (1.27) 5.00 (1.07) 0.08 
Triglycerides (mmol/L) – Mean (SD) 1.26 (0.82) 1.31 (0.83) 0.32 
Total cholesterol (mmol/L – Mean (SD) 5.93 (1.16) 6.00 (1.21) 0.34 
Breast cancer death, No (%) 342 (23.33) 83 (25.00) 0.52 
Cardiovascular death, No (%) 129 (8.80) 50 (15.06) <0.0001 
























The difference in survivals between latent classes was evaluated by displaying cumulative 
incidence functions for different causes of death by quartiles of glucose, triglycerides, and total 
cholesterol (Figure 25). Higher overall mortality was seen in Class II compared to Class I. In 
Class I, most patients died from breast cancer, whereas in Class II, most died from other causes 
apart from breast cancer and cardiovascular death. Increasing absolute numbers of deaths from 
breast cancer, cardiovascular, and other causes were seen with higher levels of all three markers 
in Class I, although there was no marked difference in relative mortality rates between each cause 
of death. On the other hand, marked differences in relative proportions of women dying from 
the three different causes were seen across levels of markers in Class II. For instance, breast 
cancer deaths were common amongst women in the lowest quartiles of glucose, triglycerides, 
and total cholesterol, but contributed little to total deaths in those with highest levels of the 
markers. More women died from cardiovascular disease with higher total cholesterol, and a 
similar association was seen between glucose and death from other causes.  
 
Finally, the risk of different causes of death was assessed by obtaining class-specific hazard 
estimates. As seen in Table 19, log-transformed triglycerides corresponded to an increased risk of 
dying from breast cancer in Class I, with a hazard ratio of 1.87 (95% CI: 1.01-3.45). No 
statistically significant associations with breast cancer death were observed for other markers or 
among women in Class II. In agreement with class-specific cumulative incidence functions, 
women in Class II had a higher risk of cardiovascular death with higher total cholesterol and a 












Figure 25. Stacked cumulative risk of death from breast cancer (BC), cardiovascular disease (CV), and 





Table 23. Hazard ratios for death from breast cancer, cardiovascular disease and other causes by levels of 
glucose, triglycerides, total cholesterol for each latent class 
 Class I Class II 
 HRa
 (95% CI) HRa (95% CI) 
Breast cancer death     
Log glucose 1.09 (0.73-1.63) 0.84 (0.45-1.57) 
Log triglycerides 1.87 (1.01-3.45) 0.91 (0.50-1.68) 
Log total cholesterol 0.84 (0.49-1.45) 1.02 (0.53-1.99) 
Cardiovascular death     
Log glucose 1.02 (0.55-1.91) 1.46 (0.97-2.20) 
Log triglycerides 7.68 (2.45-24.02) 0.71 (0.40-1.25) 
Log total cholesterol 0.86 (0.32-2.28) 2.07 (1.16-3.69) 
Other death     
Log glucose 0.73 (0.50-1.05) 2.26 (1.50-3.40) 
Log triglycerides 1.69 (0.95-3.01) 1.40 (0.74-2.64) 
Log total cholesterol 1.20 (0.65-2.24) 0.45 (0.19-1.06) 
























Chapter 4: Discussion 
To further unravel the role of inflammation in breast cancer, this thesis utilised serum markers of 
inflammation as well as related metabolic and inflammatory factors in assessing the risk, severity 
and survival of breast cancer. This chapter summarises findings within this thesis and discusses 
them in relation to existing literature and future directions of research in similar fields. Similar to 
the Methods and Results, each research question is discussed separately. 
 
4.1. Systemic inflammatory markers in relation to breast 
cancer risk, severity, and survival 
A borderline positive association was found between baseline haptoglobin and incident breast 
cancer. Although no association was observed between inflammatory markers and breast cancer 
severity at diagnosis or ER positivity, haptoglobin was positively associated with breast cancer 
death. Breast cancer patients with higher levels of CRP or haptoglobin or lower albumin levels 
were also shown to be more likely to die early from any causes. 
 
Molecular pathways linking inflammation and breast cancer have been increasingly studied. Pro-
inflammatory cytokines released during inflammation may trigger the activation of signal 
transducer and activator of transcription 3 (STAT3) and nuclear factor kappa B (NF-κB) 
signalling pathways, leading to activation of genes responsible for cell survival, proliferation, and 
angiogenesis (160, 161). Aberrant activation of STAT3 and NF-κB has been widely implicated in 
breast carcinogenesis (163, 292) and jointly contributes to an immunosuppressive tumour 
microenvironment (293). Additionally, suppressor of cytokine signalling 3 (SOCS3), an inhibitor 
of cytokine production, negatively regulates STAT3 expression and decreases proliferation in 
breast cancer cells, further linking inflammation and breast cancer (294). Apart from its effects 
on carcinogenesis, STAT3 upregulates expression of acute-phase reactants including CRP (295, 
296) and haptoglobin (297), and a synergistic effect of NF-κB on this mechanism has been 
shown. These common regulatory pathways suggest that systemic markers of inflammation may 
be useful in studying the association between inflammation and breast carcinogenesis. 
 
Analysis of CRP in relation to incident breast cancer showed a null association, which is in 
agreement with most previous studies (183, 184, 186, 188–190, 298, 299). So far, a positive 
association between serum CRP and breast cancer risk has only been documented in three 
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studies (187, 191, 300), where the largest number of breast cancer cases was 218. In addition to 
sample size, adjustments for potential confounding factors may explain the differences in 
estimates, especially BMI, since obesity has been suggested to underlie the association between 
chronic inflammation and breast cancer (301). Nevertheless, only one study showed substantial 
effect modification by overweight status (BMI </≥ 25 kg/m2) (299), whilst adjustment for BMI 
and other variables apart from age, such as hormonal factors, mostly had little impact on 
findings (184, 186, 187, 190, 300). Similarly, no marked difference was found in results when 
adjusting for BMI in the subset of women with baseline BMI, but the association between CRP 
and incident breast cancer in premenopausal women was no longer seen. This may imply that 
obesity-related inflammation in younger age plays a more important role in breast carcinogenesis 
compared to when it occurs later in life. However, there is not enough evidence suggesting that 
this could be translated to inflammation in general as no differences were seen for other markers 
upon BMI adjustment.  
 
Despite the borderline association observed with incident breast cancer, risk estimates from 
haptoglobin were more robust than from CRP when adjusted for BMI, suggesting that the 
marker is less affected by obesity. So far, this is the first study exploring the association between 
haptoglobin and breast cancer in the population setting. Previously, haptoglobin has mostly been 
investigated in the context of breast cancer treatment, where a decreased serum expression in 
response to endocrine therapy was observed (302–304). In contrast, Dowling and colleagues 
compared the serum expression of haptoglobin in 33 breast cancer patients and 15 healthy 
females and found no statistically significant differences (305). The timing of measurements and 
the characteristics of participants, however, was not addressed. Given the paucity of evidence, 
these findings indicate a potential area of research with serum haptoglobin as a marker linking 
inflammation to incident and fatal breast cancer. 
 
In this study, only prediagnostic haptoglobin showed a consistent association with breast cancer-
specific death. Nevertheless, an increased risk of early death from all causes following breast 
cancer diagnosis was found in women with higher levels of CRP, haptoglobin and WBC, and a 
higher cumulative risk of all-cause mortality with lower albumin levels. This suggests better 
overall survival in breast cancer patients with normal levels of these markers prior to diagnosis. 
Allin and colleagues also studied prediagnostic CRP and all-cause mortality in 202 women 
diagnosed with breast cancer (189), and found no statistically significant association (HR: 1.1, 
95% CI: 0.2-6.7 for CRP >3 mg/L compared to <1 mg/L, Ptrend = 0.17). Besides the different 
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measurement methods, this discrepancy may be accounted for by the low number of cases in the 
previous study, rendering the risk difference between prediagnostic CRP levels unquantifiable. In 
addition, there is evidence that postdiagnostic serum CRP may be associated with worse cancer-
specific and overall survival in breast cancer patients (306–309), which indicates a prognostic 
value of serum inflammatory markers in addition to their role in breast cancer aetiology as 
indicated in the present study. Future mechanistic investigations and clinical studies are thus 
necessary to explore their implication in underlying mechanisms of breast cancer and 
management of the disease.  
 
To sum up, in addition to being weakly linked to incident breast cancer, higher prediagnostic 
serum haptoglobin levels were associated with a higher risk of death from the disease, which 
supports a role of inflammation in breast carcinogenesis. Additionally, women with higher 
prediagnostic CRP, haptoglobin or WBC levels are at higher risk of dying early from any causes 
following breast cancer diagnosis. These analyses imply that inflammation preceding breast 
cancer may impact survival after diagnosis. Such findings suggest the importance of 
inflammation as one of the mechanisms underlying breast cancer which may be further 




4.2. Atopy and Cancer 
In the present study, atopy was associated with a lower risk of incident cancer. The inverse trend 
between serum specific IgE was more pronounced in women and among those with high total 
IgE levels. Among the most common cancers, no association was observed except for an inverse 
trend between serum specific IgE scores and risk of melanoma in the overall population. A 
similar inverse but non-statistically significant trend was observed for breast cancer. No 
associations between prediagnostic allergen-specific IgE and survival following cancer diagnosis 
were observed.  
 
A shift towards immunosuppressive immune responses is characteristic of cancer (13). 
Nevertheless, little is known about the role of humoral immune responses, particularly IgE, in 
carcinogenesis. IgE production and class-switch recombination (CSR) to IgE from other 
immunoglobulin types such as IgG are regulated by TH2, and it has been suggested that a biased 
TH2 response underlies high IgE levels in allergic individuals (310). Since only limited responses 
following allergen exposure are observed for IgE (311), it is possible that any impact on 
carcinogenesis is secondary to the biased TH2 response rather than a result of high circulating 
IgE itself. In support of this, a temporal model of IgE and IgG has been proposed, in which the 
early-response IgE undergo sequential CSR to higher-affinity IgG3, then to IgG1, IgG2, and 
finally IgG4 (312–314), the latter of which displays low immunoactivatory functions. 
Furthermore, inflammatory TH2-biased conditions such as IL-10, IL-4, VEGF and FoxP3+ 
Tregs that support class switching to IgG4 rather than IgE, and elevated IgG4 levels have been 
reported in different tumours including melanoma (315, 316). Specifically in melanoma, elevated 
serum IgG4 levels and IgG4+ B cells in patient circulation are associated with worse clinical 
outcomes, implying a bias towards an alternative rather than an IgE-biased response associated 
with melanoma cancer growth (317, 318). Taken together, these indications point toward a role 
of CSR dysregulation associated with TH2-biased response in driving the link between allergy, 
circulating IgE, and IgG4-related diseases including some cancers (319).  
 
So far, only few prospective studies reported the association between atopy according to serum 
specific IgE positivity and risk of cancer. In a recent study based on prospective cohorts in 
Denmark, Skaaby and colleagues analysed serum specific IgE of inhalant allergens in 14,849 
individuals. A lack of association between atopy and risk of overall cancer was reported, with a 
HR of 1.00 (95% CI: 0.89-1.12) for atopy versus no atopy [19]. Similarly, a lack of a precise 
association when assessing atopy against inhalant allergens in relation to overall incident cancer 
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was found. However, taking into account serum total IgE showed an inverse association. 
Differences in follow-up periods and cohort composition may explain the discrepancy in the 
findings. The present study was based on a large cohort with a median follow-up of 18.6 years. 
In comparison, the study by Skaaby and colleagues comprised five cohorts spanning over 
different time periods, with a shorter overall median follow-up of 11.8 years (320). Although 
adjustments for other risk factors such as smoking, alcohol consumption and physical activity 
were performed in the previous study (320), they did not alter any findings and therefore they are 
unlikely to explain the discrepancy with the present study in which this information was 
unavailable.  
 
For specific cancers, observational findings seem to vary by demographics and timing of specific 
IgE measurements. Two European nested case-control studies demonstrated an inverse 
association between atopy against inhalant allergens and risk of glioma in women but not men 
[20, 21], whereas no association was reported by a nested case-control study based on four U.S. 
cohorts [22]. Besides population attributes, a smaller number of cases in the latter study may 
explain such discrepancy. In case-control studies where specific IgE in cases was assessed after 
diagnosis, atopy against inhalant allergens was inversely associated with risk of lymphoid 
malignancies and positively with prostate cancer risk [23, 24]. However, no such associations 
were observed in studies where serum samples were prospectively collected before diagnosis [19, 
23, 25].  
 
In the present study population, no associations between atopy and risk of specific cancer sites 
were found which is comparable with the Danish study [19]. For breast cancer, a non-statistically 
significant inverse association between serum specific IgE scores and risk of breast cancer was 
observed in women. To date, evidence from observational studies on the role of atopy in breast 
remains unclear. In a meta-analysis, no associations between atopy or history of any allergy, 
asthma, or hay fever and breast cancer risk were suggested [8].  Interestingly, endocrine 
treatment agents for oestrogen-positive (ER+) breast cancers such as tamoxifen has been shown 
to reduce allergen-specific immunoglobulin levels including IgE in animal models of AD [30], 
which may suggest a potential interplay between immunologic and hormonal factors in breast 
cancer biology.  
 
Additionally, higher scores of specific IgE were weakly associated with lower risk of melanoma 
when both men and women were assessed, although this association was weaker in sex-specific 
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analyses. To date, there have been no other studies investigating serum specific IgE in relation to 
melanoma risk, although results with other atopy assessments have been reported. Using skin 
prick test, two prospective cohorts found that atopy against inhalant allergens was not associated 
with subsequent melanoma incidence [9, 31].  On the other hand, findings based on history of 
atopic disorders have been conflicting. Hospitalisation with asthma has been linked to lower 
incidence of melanoma [29, 32], whereas both increased [33] and reduced risks [34] of melanoma 
were reported with atopic dermatitis. This again emphasises the need to refine quantitative 
assessments of atopy, which are able to both capture relevant immunologic response and clinical 
severity. 
  
There are several caveats in assessing serum allergen-specific IgE as a marker of atopy. Allergen-
specific IgE levels represent the probability of having clinical allergic disease, therefore, use of a 
single allergen and/or cutoff to define atopy may not fully be representative of one’s allergic 
symptoms (321). In line with this notion, stronger associations were found with categories of 
specific IgE compared to the conventional single cutoff point of specific IgE levels, which 
indicates that specific IgE scores or categories may be more useful than a single cutoff point in 
assessing cancer risk. Additionally, there is an indication that the sum of specific IgE levels 
against common inhalant allergens correlates better with clinical symptoms such as wheezing 
(322) and hospitalisation with asthma (323), compared to individual levels of specific IgE. It was 
not possible to assess cumulative levels of specific IgE in this study. Therefore, future studies 
assessing allergy-related cancer susceptibility may benefit from refined criteria of atopy. 
  
In summary, this study suggests that atopy is weakly associated with a lower risk of malignancy in 
cancer-free individuals. These findings add to the evidence that immune responses involved in 
allergy contribute to the susceptibility of being diagnosed with cancer, particularly melanoma. In 
particular, these results may support a role of TH2-biased immune response in development of 
these cancers, indicated by a shift in the balance between circulating IgE and IgG subclasses 
including the low immunoactivatory IgG4, which urges further mechanistic investigations.  
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4.3. Serum Lactate Dehydrogenase and Survival Following 
Cancer Diagnosis  
In the present study, higher prediagnostic LDH corresponded to lower overall and cancer-
specific survival following cancer diagnosis. More specifically, a greater risk of dying from cancer 
was seen with increasing LDH in those diagnosed with prostate, pulmonary, colorectal, 
gastroesophageal, gynaecological or haematological cancer. Furthermore, associations between 
LDH and both all-cause and overall cancer deaths were stronger when LDH was measured 
closer to cancer diagnosis.  
 
Several plausible mechanisms may underlie the link between LDH and cancer progression. 
Rapidly proliferating cancer cells requires extreme supplies of energy and chronic hypoxia 
secondary to tumour growth activates hypoxia-inducible factor 1 (HIF-1), a key regulator of 
glycolysis and angiogenesis (324). HIF-1 drives the metabolic switch to glycolysis by stimulating 
expression of glycolytic enzymes (221) and directly repressing mitochondrial function through 
activation of pyruvate dehydrogenase kinase 1 (PDK-1) (325, 326). The subsequent 
accumulation of glycolytic metabolites may promote further HIF-1 activation, resulting in a feed-
forward stimulatory loop in cancer cells (220). HIF-1 also upregulates angiogenic factors 
including vascular endothelial growth factor-A (VEGF-A) (327), therefore linking glycolysis and 
LDH to angiogenesis and cancer progression (328, 329). However, continuous oxygen 
availability in glycolytic cancers, such as leukemia, suggests that other underlying factors may 
trigger the switch to aerobic glycolysis before hypoxia occurs (215). Additionally, the tumour-
promoting role of A and B subunits of LDH has been suggested: increased LDH-A levels are 
crucial in c-MYC-mediated cell transformation (330, 331), whereas LDH-B is necessary in 
mammalian target of rapamycin (mTOR)-mediated tumourigenesis (332). These biological 
findings imply that LDH may be relevant to tumour growth and severity, and may also play a 
role in carcinogenesis. Further supporting this notion, recent evidence showed tumourigenesis 
secondary to a lack of oxidative phosphorylation in cells deficient in mitochondrial enzyme 
succinate dehydrogenase (333, 333, 334). 
 
A prognostic value of serum LDH has been suggested in several types of cancer, particularly 
haematological malignancies. Serum LDH is a predictor of worse survival in diffuse large B-cell 
lymphoma (DLBCL) and is one of the five risk factors included in the International Prognostic 
Index (IPI) (229, 230). Similar associations with survival have been established in chronic 
myeloid and lymphocytic leukemias (234, 235) and small cell lung cancer (231, 233). In recent 
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clinical trials, elevated serum LDH has been shown as an independent predictor of overall 
survival in advanced or metastatic cancer of the breast (236), prostate (335, 336), colorectum 
(337), oesophagus (338), pancreas (339), ovary (340), nasopharynx (341, 342), gastric 
adenocarcinoma (343), hepatocellular carcinoma (344), renal cell carcinoma (345), and melanoma 
(346, 347). Summing up these studies, a recent meta-analysis demonstrated the inverse 
association between serum LDH and overall survival in solid tumours (237), although high 
publication bias was found. 
 
Corroborating previous findings, the present study found higher risks of early death among 
cancer patients with high levels of baseline serum LDH at time of diagnosis and within 3 years 
before diagnosis. However, in the site-specific analysis with cancer-specific death as the outcome 
of interest, this association was only shown in those diagnosed with prostate, pulmonary, 
colorectal, gastroesophageal, gynaecological or haematological cancer. Considering the link of 
LDH with other chronic diseases which may contribute to death (238, 239), it is therefore 
important to consider cause-specific death to gain further insight into the prognostic relevance 
of LDH. 
 
A borderline inverse trend was seen between LDH and head and neck cancer death, although 
the analysis was limited by the number of events. The unique distribution of LDH subunits (348) 
may explain different associations of serum expression of LDH with specific cancer types. 
Supporting this notion, an observation of average LDH levels measured by six-month intervals 
before diagnosis showed varying trend across different cancer sites, which may indicate a 
different extent of aerobic glycolysis with respect to cancer types. It is known that the majority 
of LDH subunits detected in the serum is LDH-B, although LDH-A exists in a lesser amount 
(226). The absence of LDH-B expression and its enzyme activities have been reported in cell 
lines of breast (349), prostate (350), gastric and pancreatic cancer (351), suggested to be driven by 
promoter hypermethylation. Since LDH-B kinetically favours the backward reaction of pyruvate-
lactate conversion (348), this may suggest that LDH-A, which mostly catalyses the formation of 
lactate, is more relevant to cancer than LDH-B (226). However, recent evidence has shown that 
higher tissue expression of LDH-B correlates to overall survival in lung cancer and treatment 
response in breast cancer (352, 353), which highlights the role of LDH-B in cancer progression. 
Given the scarcity of data regarding the long-term impact of differential LDH expression on 
cancer survival, further investigations are needed to confirm the clinical usefulness of LDH with 




In addition to the positive association between prediagnostic LDH and death following cancer 
diagnosis, the importance of timing in LDH measurement was indicated in the present study. 
LDH measured within 12 months prior to the diagnosis of cancer was shown to be strongly 
associated with overall and cancer-specific death. This finding further indicates the relevance 
between LDH and tumour severity and may imply a predictive value of LDH for cancer 
diagnosis and severity. The positive association between LDH measured within 30 to 36 months 
before diagnosis and risk of overall as well as breast cancer death further signifies the importance 
of assessing cancer-specific death given the link between LDH and other fatal diseases such as 
cardiovascular disease (238).  
 
Based on prospectively collected serum LDH, the present study demonstrated an inverse 
association between LDH and survival following diagnosis of several cancers, adding to the 
current evidence on the role of LDH in cancer progression. Future mechanistic studies are 
therefore necessary to establish whether serum LDH is a proxy of tumour growth and severity, 
which explains its association to cancer survival, or if it is also involved in early carcinogenesis.   
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4.4. Associations of Serum Glucose and Lipids with Breast 
Cancer Death  
Survival analyses with Cox regression and a latent class proportional hazards model were 
performed to assess the association between prediagnostic markers of glucose and lipid 
metabolism and death from breast cancer in female breast cancer patients. The latter method 
accounted for cardiovascular death and other death as competing risks. With Cox proportional 
hazards model, a lack of association was observed between the three markers and breast cancer 
death. However, cardiovascular death was shown as a competing event. When latent class 
proportional hazards analysis were performed, two distinct latent classes were found within this 
cohort, reflecting different susceptibilities of dying from breast cancer based on their baseline 
characteristics. Class I, comprising the majority of the study population, was associated with an 
increased risk of breast cancer death following higher triglycerides levels. Overall survival was 
worse in Class II, among which higher total cholesterol levels were associated with an increased 
risk of cardiovascular death and higher glucose with risk of death from other causes. No 
association between the three markers and breast cancer death was seen in Class II. 
 
Metabolisms of glucose and lipid have been implicated in many chronic diseases. In the context 
of cancer, an array of evidence has linked increased breast cancer incidence with aberrant levels 
of circulating glucose, triglycerides and total cholesterol at baseline (354–356). Abnormal levels 
of these markers are also associated with cardiovascular disease, which is the most common 
cause of death in general population (260, 261). This has also been demonstrated in the present 
study, as both glucose and triglycerides were associated with a higher risk of cardiovascular 
death, and the associations were stronger than those with breast cancer death. Several biological 
mechanisms are suggested to underlie this common link, such as chronic inflammation and 
insulin resistance, which may drive atherogenesis, cellular proliferation and angiogenesis (242, 
262, 263). These shared metabolic pathways may thus result in a competing risks situation, where 
individuals with similar sets of risk factors are equally at risk of dying from both breast cancer 
and cardiovascular disease. In this case, a heterogeneous association between glucose and lipid 
markers and breast cancer death may be observed, which represents subpopulations or latent 
classes with different mortality risk profiles. However, this heterogeneity in survival data is not 
addressed by common analytical methods in cancer epidemiology. 
 
Cox proportional hazards regression and latent classes proportional hazards model differ 
fundamentally in the assumptions made regarding risk correlations. In Cox, non-informative 
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censoring is assumed, which leads to the assumption of independence or no correlation between 
event times when multiple events are observed. However, in the real-world clinical observation, 
such assumptions are rarely assessable and sometimes inaccurate. The latent class proportional 
hazards model allows for the presence of heterogeneity underlying any observed risk associations 
(288) and predicts optimal parameters based on the most probable substructure of the study 
population. In the present study, this resulted in an optimal model with two latent classes. 
Overall survival was lower in Class II than Class I, which indicates the importance of taking into 
account risk associations when investigating biological markers in relation to cancer survival.  
 
Triglyceride levels were associated with early death from breast cancer in Class I. This suggests 
an importance of lipid metabolism in disease progression in a relevant subset of breast cancer 
patients, which warrants further mechanistic investigation. No statistically significant association 
with breast cancer death was observed for glucose and total cholesterol, although among Class II 
they were associated with higher risks of dying from other causes and cardiovascular disease, 
respectively. Previous studies have reported a null association for triglycerides and total 
cholesterol in relation to all-cause mortality (357) and breast cancer-specific death (358), which is 
similar to the present findings using Cox regression and in Class II as assessed by latent classes 
proportional hazards model. Likewise, a lack of association with overall death has been reported 
for glucose(244, 245). Although Class I comprised the majority of all women studied, it is 
possible that the positive association between triglycerides and Class I was diluted in the overall 
cohort, resulting in a weaker association. Therefore, it is important to consider cohort 
heterogeneity in assessing this relationship.  
 
Overall, there was a weak association between prediagnostic triglyceride levels and breast cancer 
death in the majority of women with breast cancer. On the other hand, glucose and total 
cholesterol were strongly associated with mortality from causes apart from breast cancer in the 
remaining patients, among which shorter overall survival was observed. The present study 
therefore demonstrated heterogeneity in the association between glucose, lipid markers, and 
breast cancer survival when cardiovascular death and other death were taken into account as 
competing outcomes. This implies an involvement of perturbed lipid metabolism in breast 
cancer progression and a complex interaction between baseline biological markers and co-
morbidities in determining breast cancer survival which warrants mechanistic investigations. 
Therefore, such findings highlight the importance of considering cohort heterogeneity when 
evaluating biological markers in relation to cause-specific death.  
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Chapter 5: Conclusion 
In this final chapter, the strengths and limitations of studies within this thesis are discussed, as 
well as their potential implications in future research in breast cancer aetiology. 
 
Overall, the strength of studies conducted within AMORIS lies in the prospective evaluation of 
exposures and complete follow-up of study participants. All analyses were performed at the same 
laboratory with internationally accredited and calibrated methods (265). The population in 
AMORIS was selected by analysing fresh blood samples from health check-ups in non-
hospitalised persons. However, any healthy worker effect would not influence the internal 
validity of the conducted studies. Information on race/ethnicity was not available, but the 
AMORIS cohort was similar to the general working population of Stockholm (359), which 
comprised about 80% Swedish-born individuals in 2000 (269). 
 
The following section presents more detailed explanation on strengths and limitations which may 
affect interpretation of findings from each of the four studies. 
 
5.1. Systemic inflammatory markers in relation to breast 
cancer risk, severity, and survival 
This study assessed common inflammatory markers: serum C-reactive protein, white blood cells, 
albumin and haptoglobin in relation to breast cancer. Higher prediagnostic haptoglobin 
corresponded to higher breast cancer risk, and all markers were associated with survival 
following diagnosis. 
 
To date, this is the largest prospective study assessing common serum inflammatory markers in 
relation to breast cancer. Nevertheless, there were some limitations regarding measurements of 
serum markers of inflammation. High-sensitivity CRP was not available at the time 
measurements were conducted. Thus, any CRP values below 10 mg/L were unquantifiable, 
which may have resulted in an underestimation of the association between serum CRP and 
breast cancer. Information on BMI was only available for a small proportion of the participants. 
However, a lack of effect of BMI on the association between serum inflammatory markers and 




Breast cancer is strongly affected by hormonal and reproductive factors, but in AMORIS there 
was no information on menopausal status or hormonal replacement therapy at baseline. 
However, these risk factors were taken into account by assessing parity and stratifying the 
analysis using age as a proxy for menopause. In the present study, higher parity was observed in 
women who had breast cancer, which opposes the well-accepted association between parity and 
breast cancer risk (96). Nevertheless, such discrepancy has been observed in several other 
Swedish cohorts (95, 360), and may be driven by differences in other socio-demographic factors 
beyond the scope of this thesis.  
 
Finally, systemic inflammation has been linked to other causes of death such as cardiovascular 
disease (361), which may have driven the strong association with all-cause death and 
























5.2. Atopy and Cancer 
This study demonstrated an inverse association between circulating IgE levels and incident 
cancer, which was driven largely by melanoma.  
 
In addition to being able to document the role of atopy in cancer using both serum specific and 
total IgE, this is the first study investigating the impact of prediagnostic IgE levels on cancer 
survival. Therefore, the main strength of this study was the information on objective assessments 
of atopy prior to the diagnosis of cancer. Using age as a timescale addressed the strong influence 
of age on absolute levels of specific IgE and its relative proportion to total IgE (207, 284). A 
limitation of this study is the lack of information on clinical symptoms of allergy. Although 
information on specific types of allergens was available, it was not possible to link individual 
allergens with risk of cancer due to the lack of number of cases. Furthermore, continuous levels 
of serum specific IgE were not available and analytical methods differed with total IgE, 
rendering it impractical to quantify specific IgE activity using specific to total IgE ratio (207). 
Nevertheless, the present study was able to take into account total IgE in assessing cancer risk.  
 
The population studied only included individuals who underwent IgE testing and therefore may 
not be representative of the general population. However, this is not expected to influence the 
internal validity of this study. Spurious correlations may be of concern when performing multiple 
comparisons as shown in our study. However, we planned our analyses based on prior evidence 
and our results are explicable by suggested biological pathways and findings from other studies. 
Therefore the observed association is unlikely to be spurious, although a discrepancy with the 
strength of the true association is possible due to the lack of cases. Allergy symptoms in 
participating individuals may have been confused with smoking-related respiratory disorders. To 
account for the lack of information on smoking, analyses were adjusted for history of 
hospitalisation with chronic obstructive pulmonary disease and asthma. Nevertheless, residual 
confounding may still have occurred. Lastly, analyses on specific cancer types and cause-specific 
deaths were limited by the number of cases and warrant confirmations by larger studies. 
 
In summary, the associations observed between atopy and risk of cancer, particularly in women, 
may point towards a role of T-helper 2 (TH2)-biased response in carcinogenesis. Considering the 
lack of mechanistic evidence, these findings signify a potential area for further studies. 
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5.3. Serum Lactate Dehydrogenase and Survival Following 
Cancer Diagnosis  
Findings from this study demonstrated an inverse association of baseline serum LDH with 
overall survival from breast cancer, although a weaker association was observed with breast 
cancer-specific death.  
 
Although a number of studies have indicated the association between LDH and overall survival 
(237), this is the first population-based study linking baseline LDH and cancer-specific survival. 
Moreover, prospectively collected LDH levels allowed an understanding into the relevance 
between levels of LDH and timing of cancer diagnosis. A limitation of this study is the lack of 
information on cancer treatment, and given the long period of recruitment (1986 to 1999), 
variation in management of cancer may affect timing of cancer diagnosis and its survival. 
Analyses were thus accounted for period of diagnosis in as a proxy for difference in screening 
and treatment over time. 
 
Serum LDH increases due to other conditions such as myocardial infarction, inflammation and 
tissue injury (238–240), and therefore is not a specific marker of tumour development. Higher 
LDH at baseline may otherwise indicate inflammation or other disorders involves in pathways 
leading to cancer development. However, analyses were limited to three years prior to diagnosis 
to exclude reverse causation and were adjusted for CCI to take into account other diseases which 
may have predisposed one to worse survival. Additionally, there was no information on LDH 
subunits or isoenzymes and tumour characteristics such as stage, receptor status and histological 
grade. However, associations between LDH and all-cause or specific cancer death in breast 
cancer patients were not affected by tumour stage.  
 
For lymphoma, the combination between serum LDH and tumour characteristics shows to be 
useful in predicting treatment response and prognosis (229). Future research should explore 
whether the role of LDH as a biomarker extends beyond breast cancer aetiology and 




5.4. Associations of Serum Glucose and Lipids with Breast 
Cancer Death  
Systemic inflammatory and metabolic factors have been linked to other causes of death such as 
cardiovascular disease (361), which may have driven the strong association with all-cause death 
and underestimated the effects of metabolic markers on breast cancer-specific death. This final 
study emphasised the importance of addressing cohort heterogeneity in relation to breast cancer 
survival in understanding the relationship between glucose and lipid markers and cause-specific 
death in presence of competing outcomes.  
 
The strength of this study lies in the survival analysis method used to address competing risks. 
This is the first observational study utilising latent class proportional hazards model to address 
disease-specific survival in breast cancer, taking into account cardiovascular death and other 
death as competing events. As shown in this study, the advantage of incorporating latent class 
analysis and multiple events in addition to proportional hazards regression is that it allows 
identification of subpopulations within the cohort and final survival or hazard estimates of the 
primary event. In other words, this method may offer a suitable approach when dealing with 
survival functions or hazard rates estimation in presence of competing risks. A limitation of the 
present study was the lack of data representing older breast cancer patients, which may partly 
explain the low proportion of Class II. There was no information available on tumour 
characteristics, breast cancer susceptibility genes, and treatment or other metabolic and 
endocrine factors related to breast cancer such as obesity and use of hormonal replacement 
therapy. Although residual associations with unobserved covariates were captured by the model 
through identification of latent classes, underlying characteristics of these different subgroups of 
breast cancer patients may require further integration of other relevant markers or baseline 
information.  
 
Although the latent class proportional hazards may offer a suitable approach to assess survival in 
presence of competing risks, understanding characteristics of different subgroups or latent 
classes of breast cancer patients may require further information on other relevant tumour 





5.5. Conclusions and Final Remarks 
Breast cancer is very common, resulting in socioeconomic and psychological burdens which 
impact the overall population beyond those affected. Moreover, the ageing population 
worldwide adds to the burden of breast cancer because more women will be diagnosed with the 
disease. The high survivorship of breast cancer translates to approximately 8 out of 10 women 
predicted to survive their disease for at least ten years in developed countries. Consequently, 
there are also rising numbers of breast cancer survivors at risk of developing recurrence and 
other morbidities. This emerging view of breast cancer as a chronic disease stresses out the 
escalating disease burden posed by breast cancer due to an impending rise in proportions of 
survivors with disability. Thus, there is an increasing need to understand biological mechanisms 
involved in breast carcinogenesis to allow future development of more well-defined intervention. 
 
By focusing on markers of inflammation, this thesis corroborates a role of inflammatory 
processes in the development and progression of breast cancer, which may have important 
implications in breast cancer research. More specifically, the four studies included in this thesis 
demonstrated that: 1) prediagnostic inflammation affected breast cancer incidence and affected 
survival, 2) there was an inverse association between atopy and cancer risk in women, although 
only weak associations were observed for breast cancer, 3) breast cancer patients with high 
serum LDH were at risk of early death, and 4) heterogeneous associations between triglyceride 
levels and breast cancer death were seen in presence of competing outcomes.  
 
Taken together, findings from this thesis have provided more insight into the involvement of 
cellular and humoral immune responses in breast carcinogenesis, and indicated that inflammation 
taking place prior to cancer diagnosis may implicate the clinical course of the disease. This 
knowledge suggests that aetiological factors of breast cancer are of importance in the context of 
survival and warrant further investigations to explore any prognostic value. Furthermore, since 
breast cancer is a disease with long latency, associations between inflammatory markers observed 
in the longer-term prior to diagnosis, such as those observed with haptoglobin or specific IgE in 
this thesis, may imply causal contribution to carcinogenesis, whilst markers showing short-term 
association, such as LDH in this thesis, may be related to early stages of pre-clinical cancer due 
to “reverse causality”. They may be of potential interest for early cancer diagnosis. Therefore, 
further studies investigating temporality of associations between inflammation and breast cancer 
may further identify their clinical or public health importance. Finally, from methodological 
point of view, this thesis combined conventional approaches such as Cox regression, and more 
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recent approaches such as the latent class proportional hazards. Careful considerations should be 
made in selecting the most appropriate methods, preferably at the stage of study design. 
Conventional survival analysis techniques such as Kaplan-Meier survival function and Cox 
regression have straight-forward interpretation and widely used due to their practicality, thereby 
allowing easy comparability between studies. However, certain assumptions need to be met for 
the analyses, which often contradict real-life situation. More complex analytical methods may 
liberate one from such assumptions, at the price of more challenging interpretation and 
comparability. For instance, the latent class proportional hazards employed in this thesis allowed 
insight into risk correlations between breast cancer and other outcomes, a real-life situation 
which is not easily unpicked with classic survival analyses. The observed heterogeneity implies 
promising benefit in improving risk stratification of breast cancer patients. However, further 
understanding of characteristics of subpopulations identified by the model, as well as robustness 
ascertainment of models against more complex clinical characteristics are essential to take 
forward these findings to any meaningful empirical application. 
 
In summary, findings from this study add to the knowledge of and inform scientific community 
regarding the implication of immune-related biological mechanisms in breast carcinogenesis, and 
lead to new avenues of research to explore any potential clinical importance of inflammatory and 
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Appendix A1. Metabolic serum biomarkers for the prediction of cancer: a follow-up of 



































































































































































































































Appendix A2. Prediagnostic serum inflammatory markers in relation to breast cancer 










































Appendix A3. Atopy and cancer risk: Insights from a prospective study on serum specific 
and total immunoglobulin E. Poster presented at the 2015 European Society for 
Medical Oncology (ESMO) Asia Congress, December 2015. Awarded with an 
































Appendix A4. Investigating the association between allergen-specific immunoglobulin 





















































Appendix A5. Serum lactate dehydrogenase and survival following cancer diagnosis. 
Poster presented at the 2015 European Cancer Congress, September 2015. 
































Appendix A6. Serum lactate dehydrogenase and survival following cancer diagnosis. 





























































Appendix A7. A competing risks analysis of the association between prediagnostic serum 
glucose and lipids and breast cancer survival. Poster presented at the 2015 San 
Antonio Breast Cancer Symposium, December 2015. Awarded with an American 






























Appendix A8. Prediagnostic serum glucose and lipids in relation to survival in breast 
























































































































Appendix B1. Serum leptin, C-reactive protein, and cancer mortality in the NHANES 


































































































Appendix B2. Associations of C-reactive protein, granulocytes and granulocyte-to-
lymphocyte ratio with mortality from breast cancer in non-institutionalized 
American women. Poster presented at the 2014 ESMO IMPAKT Breast Cancer 
Conference. Awarded with an ESMO Travel Grant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
237 
 
 
